DCTPep_ID,DRAMP_ID,CancerPPD_ID,DBAASP_ID,Cppsite_ID,Peptide_Name,Sequence,Sequence_Length,UniProt_ID,PubChem_CID,Origin,Type,Hemolytic_Activity,Cytotoxicity,Binding_Target,Affinity,Mechanism,Nature,x_,Predicted_Structure_ID,PDB_ID,Structure,Classification,Helicity,Linear_Cyclic,Disulfide_Bond,N_terminal_Modification,C_terminal_Modification,Other_Modification,Chiral,Molecular_weight_average,Molecular_weight_monoisotopic,pI,Absent_amino_acids,Common_amino_acids,Formula,Net_charge,Acidic_residues,Basic_residues,Polar_residues,Ext,Half_Life,Instability_index,Aliphatic_index,GRAVY,Literature,Patent_ID,Patent_Title,Other_Information,Other_Published_ID,class
DCTPep01603,Not available,Not available,Not available,Not available,"FLAK 17 C",FAKALKALLKALKAL,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01603,Not available,DCTPep01603.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1599.08,1598.06,10.48,CDEGHIMNPQRSTVWY,AL,C78H139N19O16,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.65,163.33,1.013,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01606,Not available,Not available,Not available,Not available,"FLAK50 Z8",FAKIIAKIAKIAKKIL,16,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01606,Not available,DCTPep01606.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1769.33,1768.21,10.60,CDEGHMNPQRSTVWY,IK,C87H157N21O17,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",0.19,171.25,1.050,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01608,Not available,Not available,Not available,Not available,"FLAK77",FAKKALKALKKL,12,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1358.78,1357.92,10.60,CDEGHIMNPQRSTVWY,K,C66H119N17O13,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.06,122.50,0.008,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01612,Not available,Not available,Not available,Not available,"FLAK 58",FAKKLAKKLAKAAL,14,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01612,Not available,DCTPep01612.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1500.93,1499.99,10.60,CDEGHIMNPQRSTVWY,AK,C72H129N19O15,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-2.84,119.29,0.264,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01613,Not available,Not available,Not available,Not available,"FLAK 54",FAKKLAKKLAKAL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01613,Not available,DCTPep01613.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1429.86,1428.95,10.60,CDEGHIMNPQRSTVWY,K,C69H124N18O14,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,120.77,0.146,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01614,Not available,Not available,Not available,Not available,"FLAK57",FAKKLAKKLAKLAL,14,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01614,Not available,DCTPep01614.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1543.02,1542.04,10.60,CDEGHIMNPQRSTVWY,K,C75H135N19O15,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-8.91,140.00,0.407,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01616,Not available,Not available,Not available,Not available,"Shiva 10(1-18 AC)",FAKKLAKKLKKLAKKLAK,18,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01616,Not available,DCTPep01616.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2055.71,2054.42,10.90,CDEGHIMNPQRSTVWY,K,C99H183N27O19,9,0,9,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-14.14,108.89,-0.550,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01624,Not available,Not available,Not available,Not available,"FLAK06 AM",FAKKLAKKLKKLAKLALAL,19,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01624,Not available,DCTPep01624.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2096.76,2095.43,10.78,CDEGHIMNPQRSTVWY,K,C102H186N26O20,7,0,7,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.87,149.47,0.384,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01625,Not available,Not available,Not available,Not available,"FLAK06 R-AC",FAKKLAKKLKKLAKLALAL,19,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01625,Not available,DCTPep01625.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2096.76,2095.43,10.78,CDEGHIMNPQRSTVWY,K,C102H186N26O20,7,0,7,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.87,149.47,0.384,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01627,Not available,Not available,Not available,Not available,"FLAK44 AM",FAKKLAKLAKKALAL,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01627,Not available,DCTPep01627.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1614.09,1613.08,10.60,CDEGHIMNPQRSTVWY,AK,C78H140N20O16,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-1.99,137.33,0.500,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01628,Not available,Not available,Not available,Not available,"FLAG26-D1",FAKKLAKLAKKL,12,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1358.78,1357.92,10.60,CDEGHIMNPQRSTVWY,K,C66H119N17O13,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.06,122.50,0.008,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01635,Not available,Not available,Not available,Not available,"FLAK51",FAKKLAKLALKLAKL,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01635,Not available,DCTPep01635.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1656.17,1655.12,10.60,CDEGHIMNPQRSTVWY,KL,C81H146N20O16,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-18.97,156.67,0.633,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01636,Not available,Not available,Not available,Not available,"FLAK 75",FAKKLKKLAKKL,12,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1415.87,1414.98,10.70,CDEGHIMNPQRSTVWY,K,C69H126N18O13,6,0,6,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-19.13,114.17,-0.467,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01637,Not available,Not available,Not available,Not available,"FLAK71",FAKKLKKLAKLAKKL,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01637,Not available,DCTPep01637.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1728.28,1727.19,10.78,CDEGHIMNPQRSTVWY,K,C84H154N22O16,7,0,7,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-18.97,124.00,-0.260,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01638,Not available,Not available,Not available,Not available,"FLAG26-D3",FAKKLLAKALKL,12,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1343.76,1342.91,10.48,CDEGHIMNPQRSTVWY,KL,C66H118N16O13,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.06,155.00,0.650,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01639,Not available,Not available,Not available,Not available,"FLAK90",FAKLA,5,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Not Applicable","Not Applicable",Not Applicable,Not Applicable,Not Applicable,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01640,Not available,Not available,Not available,Not available,"FLAK91B",FAKLAKKALAKLL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01640,Not available,DCTPep01640.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1414.84,1413.94,10.48,CDEGHIMNPQRSTVWY,AKL,C69H123N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,150.77,0.738,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01644,Not available,Not available,Not available,Not available,"FLAK50 Q9",FAKLFAKLAKKFAL,14,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01644,Not available,DCTPep01644.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1596.03,1595,10.48,CDEGHIMNPQRSTVWY,AK,C81H130N18O15,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-2.84,112.14,0.814,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01645,Not available,Not available,Not available,Not available,"FLAK50 Q4",FAKLLAKAFKKAL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01645,Not available,DCTPep01645.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1448.86,1447.93,10.48,CDEGHIMNPQRSTVWY,AK,C72H121N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-8.86,120.77,0.662,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01651,Not available,Not available,Not available,Not available,"FLAK 50N",FAKLLAKALKLKL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01651,Not available,DCTPep01651.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1456.92,1455.99,10.48,CDEGHIMNPQRSTVWY,L,C72H129N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-23.42,173.08,0.892,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01652,Not available,Not available,Not available,Not available,"FLAK50 Q3",FAKLLAKFLKKAL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01652,Not available,DCTPep01652.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1490.94,1489.97,10.48,CDEGHIMNPQRSTVWY,KL,C75H127N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,143.08,0.815,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01654,Not available,Not available,Not available,Not available,"FLAK50 T1",FAKLLAKLAK,10,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1102.43,1101.73,10.30,CDEGHIMNPQRSTVWY,AKL,C54H95N13O11,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.98,147.00,0.790,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01657,Not available,Not available,Not available,Not available,"FLAK 50H",FAKLLAKLAKAKL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01657,Not available,DCTPep01657.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1414.84,1413.94,10.48,CDEGHIMNPQRSTVWY,AKL,C69H123N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,150.77,0.738,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01662,Not available,Not available,Not available,Not available,"FLAK50 Q8",FAKLLAKLAKKFAL,14,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01662,Not available,DCTPep01662.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1562.02,1561.01,10.48,CDEGHIMNPQRSTVWY,AKL,C78H132N18O15,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-2.84,140.00,0.886,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01663,Not available,Not available,Not available,Not available,"FLAK50T7",FAKLLAKLAKKGL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01663,Not available,DCTPep01663.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1400.81,1399.93,10.48,CDEHIMNPQRSTVWY,KL,C68H121N17O14,4,0,4,1,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,143.08,0.569,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01664,Not available,Not available,Not available,Not available,"FLAK50 T3",FAKLLAKLAKKIL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01664,Not available,DCTPep01664.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1456.92,1455.99,10.48,CDEGHMNPQRSTVWY,KL,C72H129N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",4.45,173.08,0.946,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01667,Not available,Not available,Not available,Not available,"FLAK50 T5",FAKLLAKLAKKSL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01667,Not available,DCTPep01667.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1430.84,1429.94,10.48,CDEGHIMNPQRTVWY,KL,C69H123N17O15,4,0,4,1,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,143.08,0.538,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01669,Not available,Not available,Not available,Not available,"FLAK 50G",FAKLLAKLAKLKL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01669,Not available,DCTPep01669.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1456.92,1455.99,10.48,CDEGHIMNPQRSTVWY,L,C72H129N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-23.42,173.08,0.892,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01671,Not available,Not available,Not available,Not available,"FLAK50 Q2",FAKLLFKALKKAL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01671,Not available,DCTPep01671.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1490.94,1489.97,10.48,CDEGHIMNPQRSTVWY,KL,C75H127N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-15.39,143.08,0.815,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01672,Not available,Not available,Not available,Not available,"FLAK 50E",FAKLLKLAAKKLL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01672,Not available,DCTPep01672.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1456.92,1455.99,10.48,CDEGHIMNPQRSTVWY,L,C72H129N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-16.89,173.08,0.892,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01674,Not available,Not available,Not available,Not available,"FLAK50 Z5",FAKLWAKLAKKL,12,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1416.82,1415.9,10.48,CDEGHIMNPQRSTVY,K,C71H117N17O13,4,0,4,0,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.882","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-4.85,122.50,0.258,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01678,Not available,Not available,Not available,Not available,"FLAK62 AM",FALAKKALKKAKKAL,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01678,Not available,DCTPep01678.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1629.11,1628.09,10.70,CDEGHIMNPQRSTVWY,K,C78H141N21O16,6,0,6,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",3.67,111.33,-0.013,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01680,Not available,Not available,Not available,Not available,"FLAK94",FALALKA,7,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,732.92,732.45,8.75,CDEGHIMNPQRSTVWY,A,C36H60N8O8,1,0,1,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.56,154.29,1.700,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01682,Not available,Not available,Not available,Not available,"FLAK96F",FALALKALKK,10,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1102.43,1101.73,10.30,CDEGHIMNPQRSTVWY,AKL,C54H95N13O11,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.98,147.00,0.790,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01684,Not available,Not available,Not available,Not available,"FLAK96",FALALKALKKAL,12,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1286.67,1285.85,10.30,CDEGHIMNPQRSTVWY,AL,C63H111N15O13,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-4.98,163.33,1.125,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01688,Not available,Not available,Not available,Not available,"FLAK120",FALALKALKKL,11,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1215.59,1214.81,10.30,CDEGHIMNPQRSTVWY,L,C60H106N14O12,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-14.06,169.09,1.064,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01694,Not available,Not available,Not available,Not available,"FLAK96B",FALALKLAKKAL,12,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1286.67,1285.85,10.30,CDEGHIMNPQRSTVWY,AL,C63H111N15O13,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-4.98,163.33,1.125,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01695,Not available,Not available,Not available,Not available,"Flak 96J",FALALKLAKKL,11,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1215.59,1214.81,10.30,CDEGHIMNPQRSTVWY,L,C60H106N14O12,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-14.06,169.09,1.064,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01696,Not available,Not available,Not available,Not available,"FLAK-120D",FALALKLKKL,10,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1144.51,1143.77,10.30,CDEGHIMNPQRSTVWY,L,C57H101N13O11,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-24.96,176.00,0.990,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01698,Not available,Not available,Not available,Not available,"FLAK96C",FALKALKKAL,10,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1102.43,1101.73,10.30,CDEGHIMNPQRSTVWY,AKL,C54H95N13O11,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.98,147.00,0.790,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01700,Not available,Not available,Not available,Not available,"FLAK96D",FALLKALKKAL,11,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1215.59,1214.81,10.30,CDEGHIMNPQRSTVWY,L,C60H106N14O12,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-6.35,169.09,1.064,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01701,Not available,Not available,Not available,Not available,"Flak 96I",FALLKALLKKAL,12,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1328.75,1327.9,10.30,CDEGHIMNPQRSTVWY,L,C66H117N15O13,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-4.98,187.50,1.292,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01702,Not available,Not available,Not available,Not available,"FLAK96G",FALLKL,6,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,703.92,703.46,8.75,CDEGHIMNPQRSTVWY,L,C36H61N7O7,1,0,1,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-19.97,211.67,2.017,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01703,Not available,Not available,Not available,Not available,"FAGVL",FAVGLRAIKRALKKLRRGVRKVAKDL,26,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01703,Not available,DCTPep01703.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2963.7,2961.9,12.19,CEHMNPQSTWY,KR,C134H244N46O29,9,1,10,2,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",39.41,123.85,-0.154,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01705,Not available,Not available,Not available,Not available,"FLAK50 Q10",FKLAFKLAKKAFL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01705,Not available,DCTPep01705.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1524.96,1523.96,10.48,CDEGHIMNPQRSTVWY,K,C78H125N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-26.95,113.08,0.738,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01706,Not available,Not available,Not available,Not available,"FKRLA",FKRLAKIKVLRLAKIKR,17,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01706,Not available,DCTPep01706.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2081.71,2080.42,12.32,CDEGHMNPQSTWY,K,C98H181N31O18,8,0,8,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",25.28,143.53,-0.118,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01707,Not available,Not available,Not available,Not available,"KSL-7",FKVKFKVKVK,10,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1250.64,1249.83,10.60,ACDEGHILMNPQRSTWY,K,C63H107N15O11,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-55.17,87.00,-0.130,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep00008,Not available,Not available,Not available,Not available,"Aurein 3.1",GLFDIVKKIAGHIAGSI,17,P69021##P69020,Not available,"Southern bell frog",Native peptide,"Not available","Not available","Not available",Not available,"Anticancer activity is due to penetration and disruption of the membranes of the cancer cells",Anticancer; Antimicrobial,Not available,DCTPep00008,Not available,DCTPep00008.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,1739.09,1738.01,8.60,CEMNPQRTWY,I,C81H135N21O21,2,1,3,4,"Should not be visible by UV spectrophotometry.","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",30.84,143.53,0.935,"10951191++The antibiotic and anticancer active aurein peptides from the Australian Bell Frogs Litoria aurea and Litoria raniformis the solution structure of aurein 1.2++10.1046/j.1432-1327.2000.01536.x++2000",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep00327,Not available,Not available,Not available,Not available,"Z4",KAAKKAWKAAKKAAKWWKKAA,21,Not available,Not available,"Synthetic",Synthetic peptide,"MRC-5: EC53=78 μM","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00327,Not available,DCTPep00327.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2369.93,2368.44,10.90,CDEFGHILMNPQRSTVY,AK,C114H185N33O22,9,0,9,0,"Ext. coefficient    16500##Abs 0.1% (=1 g/l)   6.962","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",9.52,42.86,-1.029,"22057278++Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity++10.1074/jbc.M111.279281++2012",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep00329,Not available,Not available,Not available,Not available,"Z3",KAAKKAWKAWKKAAKAAWKKAA,22,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00329,Not available,DCTPep00329.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2441.01,2439.47,10.90,CDEFGHILMNPQRSTVY,A,C117H190N34O23,9,0,9,0,"Ext. coefficient    16500##Abs 0.1% (=1 g/l)   6.759","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",9.55,45.45,-0.900,"22057278++Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity++10.1074/jbc.M111.279281++2012",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep03977,Not available,Not available,15133,Not available,"Z1",KAAKKWAKAAKKWAKAWKKAA,21,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,2369.93,2368.44,10.90,CDEFGHILMNPQRSTVY,AK,C114H185N33O22,9,0,9,0,"Ext. coefficient    16500##Abs 0.1% (=1 g/l)   6.962","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-4.79,42.86,-1.029,"22057278++Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity++Not available++2012",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep00332,Not available,Not available,Not available,Not available,"Z2",KAAKKWAKAWKKAAKAWKKAA,21,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00332,Not available,DCTPep00332.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2369.93,2368.44,10.90,CDEFGHILMNPQRSTVY,AK,C114H185N33O22,9,0,9,0,"Ext. coefficient    16500##Abs 0.1% (=1 g/l)   6.962","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",2.37,42.86,-1.029,"22057278++Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity++10.1074/jbc.M111.279281++2012",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep01717,Not available,Not available,Not available,Not available,"PYL-ME",KIAKVALAKLGIGAVLKVLTTGL,23,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01717,Not available,DCTPep01717.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2277.91,2276.49,10.48,CDEFHMNPQRSWY,L,C107H197N27O26,4,0,4,5,"Should not be visible by UV spectrophotometry.","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-19.97,173.91,1.287,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01718,Not available,Not available,Not available,Not available,"KSL-1",KKVVFKVKFK,10,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1250.64,1249.83,10.60,ACDEGHILMNPQRSTWY,K,C63H107N15O11,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-40.92,87.00,-0.130,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01721,Not available,Not available,Not available,Not available,"FLAK99",KLALKLALKALKAAKLA,17,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01721,Not available,DCTPep01721.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1764.31,1763.21,10.60,CDEFGHIMNPQRSTVWY,AL,C84H158N22O18,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-20.55,172.94,0.829,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01722,Not available,Not available,Not available,Not available,"FLAK100-CO2H",KLLKLLLKLYKKLLKLL,17,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01722,Not available,DCTPep01722.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2081.83,2080.48,10.40,ACDEFGHIMNPQRSTVW,L,C105H193N23O19,6,0,6,1,"Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.716","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-30.54,229.41,0.782,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01726,Not available,Not available,Not available,Not available,"FLAK93",KWKLF,5,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Not Applicable","Not Applicable",Not Applicable,Not Applicable,Not Applicable,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep00004,Not available,Not available,Not available,Not available,"CA-MA1",KWKLFKKIKFLHSAKKF,17,Not available,Not available,"Ceropin-Magainin hybrid peptides",Synthetic peptide,"Human erythrocytes: Hemolysis 0% (100 μM)","NIH-3T3 fibroblast: IC50>100 μM","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00004,1D9L,DCTPep00004.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,2177.75,2176.34,10.78,CDEGMNPQRTVY,K,C110H173N27O19,8,0,8,1,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.526","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-14.41,74.71,-0.582,"10675500++Effects of the hinge region of cecropin A(1-8)-magainin 2(1-12), a synthetic antimicrobial peptide, on liposomes, bacterial and tumor cells++10.1016/s0005-2736(99)00210-2++2000",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep00041,Not available,Not available,Not available,Not available,"C-5",KWKLFKKIPHLAKKF,15,Not available,Not available,"Ceropin A",Synthetic peptide,"Human erythrocytes: hemolysis: 0%=100 µM; hemolysis: 0%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM","NIH 3T3: IC50=100.0< µM","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00041,Not available,DCTPep00041.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,1912.44,1911.2,10.70,CDEGMNQRSTVY,K,C97H154N24O16,7,0,7,0,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.876","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-13.93,84.67,-0.640,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep00046,Not available,Not available,Not available,Not available,"C-10",KWKLFKKIPKFLH,13,Not available,Not available,"Ceropin A",Synthetic peptide,"Human erythrocytes: hemolysis: 7.6%=100 µM; hemolysis: 3.6%=50 µM; hemolysis: 0.5%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM","NIH 3T3: IC50=100.0< µM","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00046,Not available,DCTPep00046.cif,Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,1713.19,1712.07,10.60,ACDEGMNQRSTVY,K,C88H137N21O14,6,0,6,0,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.210","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-17.61,90.00,-0.577,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep00044,Not available,Not available,Not available,Not available,"C-8",KWKLFKKIPKFLHL,14,Not available,Not available,"Ceropin A",Synthetic peptide,"Human erythrocytes: hemolysis: 0%=100 µM; hemolysis: 0%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM","NIH 3T3: IC50=100.0< µM","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00044,Not available,DCTPep00044.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,1826.35,1825.15,10.60,ACDEGMNQRSTVY,K,C94H148N22O15,6,0,6,0,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.011","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-15.64,111.43,-0.264,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep00040,Not available,Not available,Not available,Not available,"C-4",KWKLFKKIPKFLHLAK,16,Not available,Not available,"Ceropin A",Synthetic peptide,"Human erythrocytes: hemolysis: 0%=100 µM; hemolysis: 0%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM","NIH 3T3: IC50=100 µM","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00040,Not available,DCTPep00040.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,2025.6,2024.28,10.70,CDEGMNQRSTVY,K,C103H165N25O17,7,0,7,0,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.715","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-12.43,103.75,-0.362,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep00043,Not available,Not available,Not available,Not available,"C-7",KWKLFKKIPLAKKF,14,Not available,Not available,"Ceropin A",Synthetic peptide,"Human erythrocytes: hemolysis: 0%=100 µM; hemolysis: 0%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM","NIH 3T3: IC50=100.0< µM","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00043,Not available,DCTPep00043.cif,Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,1775.3,1774.14,10.70,CDEGHMNQRSTVY,K,C91H147N21O15,6,0,6,0,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.098","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-15.64,90.71,-0.457,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep00039,Not available,Not available,Not available,Not available,"C-3",KWKLFKKIPLHLAKKF,16,Not available,Not available,"Ceropin A",Synthetic peptide,"Human erythrocytes: hemolysis: 4.7%=100 µM; hemolysis: 1.2%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM","NIH 3T3: IC50=100.0< µM","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00039,Not available,DCTPep00039.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,2025.6,2024.28,10.70,CDEGMNQRSTVY,K,C103H165N25O17,7,0,7,0,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.715","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-12.43,103.75,-0.362,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep00045,Not available,Not available,Not available,Not available,"C-9",KWKLFKKIPLKKF,13,Not available,Not available,"Ceropin A",Synthetic peptide,"Human erythrocytes: hemolysis: 6.2%=100 µM; hemolysis: 2.9%=50 µM; hemolysis: 0.3%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM","NIH 3T3: IC50=100.0< µM","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00045,Not available,DCTPep00045.cif,Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,1704.22,1703.1,10.70,ACDEGHMNQRSTVY,K,C88H142N20O14,6,0,6,0,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.227","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-24.14,90.00,-0.631,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep01708,Not available,Not available,Not available,Not available,"CA (1-7) Shiva10 (1-16)-COOH",KWKLFKKKTKLFKKFAKKLAKKL,23,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01708,Not available,DCTPep01708.cif,ACP,Not available,Linear,"Not available","Free",Free,None,L,2879.75,2877.89,11.04,CDEGHIMNPQRSVY,K,C144H244N36O25,12,0,12,1,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.910","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-18.27,76.52,-0.922,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01729,Not available,Not available,Not available,Not available,"CA (1-7) Shiva10 (1-16)",KWKLFKKKTKLFKKFAKKLAKKL,23,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01729,Not available,DCTPep01729.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2879.75,2877.89,11.04,CDEGHIMNPQRSVY,K,C144H244N36O25,12,0,12,1,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.910","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-18.27,76.52,-0.922,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep00251,Not available,Not available,Not available,Not available,"L6A",KWKSFAKTFKSAKKTVLHTALKAISS,26,Not available,Not available,"PeptideV13K",Synthetic peptide,"Human red blood cells: MHC>334.4 μmol/L","Not available","Not available",Not available,"Peptides killed cancer cells with a fast necrotic mechanism causing cell membrane lysis",Anticancer,Not available,DCTPep00251,Not available,DCTPep00251.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Acetylation",Amidation,None,L,2907.5,2905.69,10.78,CDEGMNPQRY,K,C136H224N36O34,8,0,8,7,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.892","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",9.82,71.54,-0.292,"21252288++Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework++10.1158/1535-7163.MCT-10-0811++2011##15677462++Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index++10.1074/jbc.M413406200++2005",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep00248,Not available,Not available,Not available,Not available,"L17A/L21A",KWKSFLKTFKSAKKTVAHTAAKAISS,26,Not available,Not available,"PeptideV13K",Synthetic peptide,"Human red blood cells: MHC>334.4 μmol/L","Not available","Not available",Not available,"Peptides killed cancer cells with a fast necrotic mechanism causing cell membrane lysis",Anticancer,Not available,DCTPep00248,Not available,DCTPep00248.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Acetylation",Amidation,None,L,2865.41,2863.64,10.78,CDEGMNPQRY,K,C133H218N36O34,8,0,8,7,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.919","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",6.56,60.38,-0.369,"21252288++Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework++10.1158/1535-7163.MCT-10-0811++2011##15677462++Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index++10.1074/jbc.M413406200++2005",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep02398,Not available,Not available,DBAASPS_4584,Not available,"MAP-04-03",KWLRRVWRWWR,11,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide##Membrane lysis,Not available,Linear,"Not available","Free",Amidation,None,L,1728.08,1726.98,12.48,ACDEFGHIMNPQSTY,RW,C85H122N28O12,5,0,5,0,"Ext. coefficient    22000##Abs 0.1% (=1 g/l)  12.731","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",141.96,61.82,-1.591,"23993331++Anticancer activities of an antimicrobial peptide derivative of Ixosin-B amide++10.1016/j.bmcl.2013.07.063++2013",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep01730,Not available,Not available,Not available,Not available,"FLAK98",KYKKALKKLAKLL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01730,Not available,DCTPep01730.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1545.03,1544.05,10.40,CDEFGHIMNPQRSTVW,K,C75H137N19O15,6,0,6,1,"Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.964","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-10.36,135.38,-0.454,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01731,Not available,Not available,Not available,Not available,"Flak 96L",LKKLAKLALAF,11,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1215.59,1214.81,10.30,CDEGHIMNPQRSTVWY,L,C60H106N14O12,3,0,3,0,"Should not be visible by UV spectrophotometry.","5.5 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-14.06,169.09,1.064,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01734,Not available,Not available,Not available,Not available,"SB-37 AC",MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG,38,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01734,Not available,DCTPep01734.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,4089,4086.41,10.73,CDHQSTY,K,C188H320N54O45S1,7,2,9,7,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.345","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",31.93,105.26,-0.008,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01735,Not available,Not available,Not available,Not available,"SB-37 AM",MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG,38,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01735,Not available,DCTPep01735.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,4089,4086.41,10.73,CDHQSTY,K,C188H320N54O45S1,7,2,9,7,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.345","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",31.93,105.26,-0.008,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01076,Not available,Not available,Not available,Not available,"Shiva-1",MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG,38,Not available,Not available,"Magainin",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep01076,Not available,DCTPep01076.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,4243.1,4240.46,12.13,CEHNSTY,R,C189H322N64O45S1,7,2,9,5,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.296","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",61.74,107.89,-0.097,"7849420++Preliminary experimental anticancer activity of cecropins++Not available++1994",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep00137,Not available,Not available,Not available,Not available,"Pep27anal1",MWKWFHNVLSSWQLLADKRPARDYNRK,27,Not available,Not available,"S. pneumoniae",Synthetic peptide,"Human RBCs(0% hemolysis at 0.19 μM, 0.39 μM, 0.78 μM, 1.56 μM, 3.12 μM, 6.25 μM, 12.5 μM)","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00137,Not available,DCTPep00137.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,3446.98,3444.78,10.43,CEGIT,KLRW,C159H237N47O38S1,5,2,7,5,"Ext. coefficient    17990##Abs 0.1% (=1 g/l)   5.219","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",45.59,61.48,-1.081,"16004618++Functional and structural characteristics of anticancer peptide Pep27 analogues++10.1186/1475-2867-5-21++2005",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep01737,Not available,Not available,Not available,Not available,"FLAK50 Q1V",VAKFLAKFLKKAL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01737,Not available,DCTPep01737.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1476.91,1475.96,10.48,CDEGHIMNPQRSTWY,K,C74H125N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",2.7,135.38,0.846,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01738,Not available,Not available,Not available,Not available,"D2A21V",VAKKFAKKFKKFAKKFAKFAFAF,23,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01738,Not available,DCTPep01738.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2727.42,2725.64,10.90,CDEGHILMNPQRSTWY,K,C140H212N32O24,9,0,9,0,"Should not be visible by UV spectrophotometry.","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",3.03,38.70,-0.022,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01740,Not available,Not available,Not available,Not available,"FLAK 25 AM V",VAKKLAKLAKKLAKLALAL,19,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01740,Not available,DCTPep01740.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1991.62,1990.38,10.70,CDEFGHIMNPQRSTWY,AKL,C95H179N25O20,6,0,6,0,"Should not be visible by UV spectrophotometry.","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-8.4,170.00,0.758,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01741,Not available,Not available,Not available,Not available,"FLAK43 AM V",VAKKLAKLAKKLLAL,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01741,Not available,DCTPep01741.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1608.13,1607.12,10.60,CDEFGHIMNPQRSTWY,KL,C77H146N20O16,5,0,5,0,"Should not be visible by UV spectrophotometry.","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-7.65,176.00,0.727,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01744,Not available,Not available,Not available,Not available,"FLAK50T8",VAKLLAKLAKKVL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01744,Not available,DCTPep01744.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1394.85,1393.97,10.48,CDEFGHIMNPQRSTWY,KL,C67H127N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-10.36,187.69,1.031,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01745,Not available,Not available,Not available,Not available,"Hecate AC V",VALALKALKKALKKLKKALKKAL,23,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01745,Not available,DCTPep01745.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2489.3,2487.74,10.90,CDEFGHIMNPQRSTWY,K,C119H226N32O24,9,0,9,0,"Should not be visible by UV spectrophotometry.","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-12.58,157.39,0.283,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01746,Not available,Not available,Not available,Not available,"Hecate AM V",VALALKALKKALKKLKKALKKAL,23,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01746,Not available,DCTPep01746.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2489.3,2487.74,10.90,CDEFGHIMNPQRSTWY,K,C119H226N32O24,9,0,9,0,"Should not be visible by UV spectrophotometry.","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-12.58,157.39,0.283,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep01748,Not available,Not available,Not available,Not available,"FLAK-120G",VALALKALKKL,11,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1167.54,1166.81,10.30,CDEFGHIMNPQRSTWY,L,C56H106N14O12,3,0,3,0,"Should not be visible by UV spectrophotometry.","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-14.06,195.45,1.191,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep00974,Not available,Not available,Not available,Not available,"Tritrp-Arg",VRRFPWWWPFLRR,13,Not available,Not available,"porcine cathelicidin peptide",Synthetic peptide,"RBC: IC50=62.2 µM","PBMC: IC50=18.4 µM","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00974,Not available,DCTPep00974.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1902.28,1901.05,12.48,ACDEGHIKMNQSTY,R,C96H132N28O14,4,0,4,0,"Ext. coefficient    16500##Abs 0.1% (=1 g/l)   8.674","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",139.58,52.31,-0.792,"32126228++Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin++10.1016/j.bbamem.2020.183228++2020",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep00975,Not available,Not available,Not available,Not available,"Tritrpticin",VRRFPWWWPFLRR,13,Not available,Not available,"porcine cathelicidin peptide",Synthetic peptide,"RBC: IC50 ≥ 65 µM","PBMC: IC50=40.6 µM","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00975,Not available,DCTPep00975.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,1902.28,1901.05,12.48,ACDEGHIKMNQSTY,R,C96H132N28O14,4,0,4,0,"Ext. coefficient    16500##Abs 0.1% (=1 g/l)   8.674","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",139.58,52.31,-0.792,"32126228++Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin++10.1016/j.bbamem.2020.183228++2020##18815734++Effect of dimerization of a beta-turn antimicrobial peptide, PST13-RK, on antimicrobial activity and mammalian cell toxicity++10.1007/s10529-008-9848-5++2009",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep01750,Not available,Not available,Not available,Not available,"FLAK-120F",WALAL,5,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Not Applicable","Not Applicable",Not Applicable,Not Applicable,Not Applicable,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,inactive - exp
DCTPep00033,Not available,Not available,Not available,Not available,"N-5",WKKIPKFLHLAKKF,14,Not available,Not available,"Ceropin A",Synthetic peptide,"Human erythrocytes: hemolysis: 0%=100 µM; hemolysis: 0%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM","NIH 3T3: IC50=100.0< µM","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00033,Not available,DCTPep00033.cif,Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,1784.27,1783.1,10.60,CDEGMNQRSTVY,K,C91H142N22O15,6,0,6,0,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.082","2.8 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",1.16,90.71,-0.407,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",Not available,Not available,"Not available",Not available,inactive - exp
DCTPep02037,Not available,4429,DBAASPR_4320,Not available,"EP5, Antimicrobial peptide OEP3121",ACSAG,5,P84182,Not available,"Eisenia fetida (Red wiggler worm)",Native peptide,"Not available","Not available","Not available",Not available,"Mechanisms of EP5 may be directed to enter into cells to influence duplication and synthesis. Another mechanism was to form multimers by the connection of disulfide bonds with cysteins, also to make a hole in the cell membrane and induce the contents out of the cell.",Anticancer; Antimicrobial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Not Applicable","Not Applicable",Not Applicable,Not Applicable,Not Applicable,"Not available++A novel antimicrobial vermipeptide family from earthworm Eisenia fetida++10.1016/j.ejsobi.2007.08.048++2007",Not available,Not available,"Not available",Not available,negative
DCTPep04777,DRAMP02459,Not available,Not available,Not available,"L-amino-acid oxidase",ADDKNPLEECFRETDYEEFLEIARNGLKATSNPKRVV,37,P0DI88,Not available,"Bothrops jararaca",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Not available,"Not available","Free",Free,None,L,4298.75,4296.11,4.65,HMQW,E,C186H294N52O63S1,-3,9,6,9,"Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.347, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.347, assuming all Cys residues are reduced","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",42.04,65.95,-0.986,"20615423++Not available++Not available++Not available##19101583++Not available++Not available++Not available##18346051++Not available++Not available++Not available",Not available,Not available,"Not available",Not available,negative
DCTPep04654,DRAMP01162,Not available,Not available,Not available,"Buforin-1",AGRGKQGGKVRAKAKTRSSRAGLQFPVGRVHRLLRKGNY,39,P55897,Not available,"Bufo bufo",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,4LD9,Not available,Cancer therapy related peptides,Not available,Not available,"Not available","Free",Free,None,L,4262.99,4260.46,12.41,CDEIMW,GR,C184H318N70O47,13,0,13,12,"Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.350","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",46.13,62.56,-0.992,"8946958++Not available++Not available++Not available##8573171++Not available++Not available++Not available##30570475++Not available++Not available++Not available##26091834++Not available++Not available++Not available##23724649++Not available++Not available++Not available##21672084++Not available++Not available++Not available##10890923++Not available++Not available++Not available",Not available,Not available,"Not available",Not available,negative
DCTPep03438,Not available,Not available,2135,Not available,"Moricin-1",AKIPIKAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKH,42,O96059##P82818,Not available,"Animalia",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep03438,1KV4,DCTPep03438.cif,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,4543.52,4540.73,11.36,CEMQWY,K,C208H358N62O51,11,1,12,9,"Should not be visible by UV spectrophotometry.","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",8.32,100.00,-0.210,"Not available++Antimicrobial peptide moricin induces ROS mediated caspase-dependent apoptosis in human triple negative breast cancer via suppression of notch pathway++Not available++2022##8530391++Moricin, a novel type of antibacterial peptide isolated from the silkworm, Bombyx mori++Not available++1995",Not available,Not available,"Not available",Not available,negative
DCTPep00326,Not available,Not available,Not available,Not available,"Z8",AWKKWAKAWKWAKAKWWAKAA,21,Not available,Not available,"Synthetic",Synthetic peptide,"MRC-5: EC57=17 μM","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00326,Not available,DCTPep00326.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2601.14,2599.45,10.78,CDEFGHILMNPQRSTVY,A,C132H186N34O22,7,0,7,0,"Ext. coefficient    33000##Abs 0.1% (=1 g/l)  12.687","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-11.95,38.10,-0.871,"22057278++Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity++10.1074/jbc.M111.279281++2012",Not available,Not available,"Not available",Not available,negative
DCTPep04723,Not available,Not available,Not available,Not available,"Kalata B1",CGETCVGGTCNTPGCTCSWPVCTRNGLPV,29,P56254,Not available,"Oldenlandia affinis",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,1ZNU##2JUE##1NB1,Not available,Cancer therapy related peptides,Not available,Not available,"Not available","Free",Free,None,L,2916.34,2914.2,5.96,ADFHIKMQY,C,C117H187N35O40S6,0,1,1,19,"Ext. coefficient     5875##Abs 0.1% (=1 g/l)   2.015, assuming all pairs of Cys residues form cystines##Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.886, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",41.41,43.45,0.152,"23468118++Not available++Not available++Not available##21928440++Not available++Not available++Not available##16817894++Not available++Not available++Not available##12482868++Not available++Not available++Not available##10747913++Not available++Not available++Not available##10441158++Not available++Not available++Not available",Not available,Not available,"Not available",Not available,negative
DCTPep00023,Not available,4431,Not available,Not available,"HNP-2",CYCRIPACIAGERRYGTCIYQGRLWAFCC,29,P59666##P59665##Q6EZE9##G3QPD5,Not available,"Human alpha-defensins",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00023,Not available,DCTPep00023.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Cyclic,"Cys1<--->Cys29; Cys9<--->Cys18; Cys8<--->Cys28","Free",Free,None,L,3377.01,3374.52,8.67,DHKMNSV,C,C147H223N43O37S6,3,1,4,13,"Ext. coefficient    10345##Abs 0.1% (=1 g/l)   3.063, assuming all pairs of Cys residues form cystines##Ext. coefficient     9970##Abs 0.1% (=1 g/l)   2.952, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",42.13,64.14,0.248,"11943716++Human alpha-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation++10.1016/s0002-9440(10)62558-8++2002",Not available,Not available,"Not available",Not available,negative
DCTPep00567,Not available,Not available,Not available,Not available,"Defensin AFP1 / Hs-AFP1",DGVKLCDVPSGTWSGHCGSSSKCSQQCKDREHFAYGGACHYQFPSVKCFCKRQC,54,Not available,Not available,"Heuchera sanguinea",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep00567,Not available,DCTPep00567.cif,Cancer therapy related peptides,Not available,Cyclic,"Cys6<--->Cys54; Cys17<--->Cys39; Cys23<--->Cys48; Cys27<--->Cys50","Free",Free,None,L,5948.71,5944.58,8.49,IMN,CS,C251H378N76O77S8,6,4,10,24,"Ext. coefficient     8980##Abs 0.1% (=1 g/l)   1.510, assuming all pairs of Cys residues form cystines##Ext. coefficient     8480##Abs 0.1% (=1 g/l)   1.426, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",57.07,27.04,-0.613,"26248029++Synergistic Activity of the Plant Defensin HsAFP1 and Caspofungin against Candida albicans Biofilms and Planktonic Cultures++10.1371/journal.pone.0132701++2015",Not available,Not available,"Not available",Not available,negative
DCTPep00109,Not available,Not available,Not available,Not available,"P. sajor-caju Rnase",DNGEAGRAAR,10,Not available,Not available,"Pleurotus sajor-caju",Native peptide,"Not available","Mouse splenocytes: IC50=0.065 µM","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide##Affect cell cycle,Not available,Linear,"Not available","Free",Free,None,L,1016.04,1015.48,6.07,CFHIKLMPQSTVWY,A,C38H65N17O16,0,2,2,3,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-13.57,30.00,-1.490,"15003351++A ribonuclease with antimicrobial, antimitogenic and antiproliferative activities from the edible mushroom Pleurotus sajor-caju++10.1016/j.peptides.2003.11.012++2004",Not available,Not available,"Not available",Not available,negative
DCTPep01690,Not available,Not available,Not available,Not available,"FLAK06 AC",FALALKALKKLKKALKKAL,19,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01690,Not available,DCTPep01690.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2096.76,2095.43,10.78,CDEGHIMNPQRSTVWY,K,C102H186N26O20,7,0,7,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.87,149.47,0.384,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,negative
DCTPep01691,Not available,Not available,Not available,Not available,"FLAK06 AM",FALALKALKKLKKALKKAL,19,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01691,Not available,DCTPep01691.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2096.76,2095.43,10.78,CDEGHIMNPQRSTVWY,K,C102H186N26O20,7,0,7,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.87,149.47,0.384,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,negative
DCTPep00155,Not available,1528##1534##1540,DBAASPS_3393,Not available,"LL-37(17-29)",FKRIVQRIKDFLR,13,P49913,Not available,"LL-37,a series of peptide fragments",Synthetic peptide,"Human erythrocytes: Not active up to 500 µg/ml","HBMEC: LC50=41 µM; DLF lung fibroblasts: IC50=29.3 μg/ml","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00155,2FBS,DCTPep00155.cif,ACP##Tumor active peptide##Induce apoptosis,Not available,Linear,"Not available","Free",Amidation,None,L,1719.11,1718.05,11.72,ACEGHMNPSTWY,R,C80H135N25O17,4,1,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",18.7,112.31,-0.438,"16637646++Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region++10.1021/ja0584875++2005##32567085++Cationic amphipathic peptide analogs of cathelicidin LL-37 as a probe in the development of antimicrobial/anticancer agents++10.1002/psc.3254++2020",Not available,Not available,"Not available",Not available,negative
DCTPep02285,Not available,Not available,DBAASPR_4935,Not available,"Temporin-1Oc",FLPLLASLFSRLF,13,Not available,Not available,"Rana ornativentris",Native peptide,"Human erythrocytes: 50% Hemolysis<12.5 µM","HaCat: LC50=50 µM","Not available",Not available,"Not available",Anticancer; Antimicrobial; Antifungal,Not available,DCTPep02285,Not available,DCTPep02285.cif,ACP##Tumor active peptide##Membrane lysis,Not available,Linear,"Not available","Free",Amidation,None,L,1523.88,1522.89,9.75,CDEGHIKMNQTVWY,L,C77H118N16O16,1,0,1,2,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",38.86,157.69,1.654,"29842923++Antibacterial, antifungal, anticancer activities and structural bioinformatics analysis of six naturally occurring temporins++10.1016/j.peptides.2018.05.011++2018",Not available,Not available,"Not available",Not available,negative
DCTPep02035,Not available,Not available,Not available,Not available,"Combi-2",FRWWHR,6,Not available,Not available,"porcine cathelicidin peptide",Synthetic peptide,"RBC: IC50 ≥ 65 µM","PBMC: IC50 ≥ 65 µM","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,987.13,986.5,12.00,ACDEGIKLMNPQSTVY,RW,C49H62N16O7,3,0,3,0,"Ext. coefficient    11000##Abs 0.1% (=1 g/l)  11.143","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",143.27,0.00,-1.867,"32126228++Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin++10.1016/j.bbamem.2020.183228++2020",Not available,Not available,"Not available",Not available,negative
DCTPep04163,Not available,Not available,17933,Not available,"Brevinin-2DYd",GIFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC,33,P0C5X4,Not available,"Synthetic",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Cyclic,"Cys27<--->Cys33","Free",Free,None,L,3318,3315.84,9.24,HMPRTWY,G,C147H254N40O42S2,3,2,5,12,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.038, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",1.56,117.88,0.491,"34073203++Prediction of Anticancer Peptides with High Efficacy and Low Toxicity by Hybrid Model Based on 3D Structure of Peptides++Not available++2021##17688900++Cytolytic peptides belonging to the brevinin-1 and brevinin-2 families isolated from the skin of the Japanese brown frog, Rana dybowskii++Not available++2007",Not available,Not available,"Not available",Not available,negative
DCTPep00257,Not available,Not available,Not available,Not available,"Ranatuerin-2Lb",GILSSIKGVAKGVAKNVAAQLLDTLKCKITGC,32,Not available,Not available,"Rana luteiventris; Rana pretiosa",Native peptide,"Human erythrocytes: 50% Hemolysis>100 µM; Sheep erythrocytes: <10% Hemolysis=256 µM","HEK293T: IC50=63.16 µM","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep00257,Not available,DCTPep00257.cif,ACP##Tumor active peptide,Not available,Cyclic,"Cys27<--->Cys32","Free",Free,None,L,3200.89,3198.82,9.60,EFHMPRWY,K,C140H251N39O41S2,4,1,5,11,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.039, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-1.54,125.00,0.591,"34073203++Prediction of Anticancer Peptides with High Efficacy and Low Toxicity by Hybrid Model Based on 3D Structure of Peptides++10.3390/ijms22115630++2021##21295070++Host defense peptides in skin secretions of the Oregon spotted frog Rana pretiosa: implications for species resistance to chytridiomycosis++10.1016/j.dci.2011.01.017++2011",CN113855783A,Not available,"Not available",Not available,negative
DCTPep01057,Not available,Not available,Not available,Not available,"Brevinin-2DYb",GLFDVVKGVLKGAGKNVAGSLLEQLKCKLSGGC,33,Not available,Not available,"Rana dybowskii",Native peptide,"Sheep erythrocytes: <10% Hemolysis=256 µM","HEK293T cells: IC50=50.66 µM","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep01057,Not available,DCTPep01057.cif,ACP##Tumor active peptide,Not available,Cyclic,"Cys27<--->Cys33","Free",Free,None,L,3289.94,3287.81,9.24,HIMPRTWY,G,C145H250N40O42S2,3,2,5,12,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.038, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",4.13,112.12,0.397,"34073203++Prediction of Anticancer Peptides with High Efficacy and Low Toxicity by Hybrid Model Based on 3D Structure of Peptides++10.3390/ijms22115630++2021",Not available,Not available,"Not available",Not available,negative
DCTPep04653,Not available,Not available,3934,Not available,"Maculatin 1.1 D",GLFGVLAKVAAHVVPAIAEHF,21,MCU11_LITGE##P82066,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,2MMJ##2MN8##2MN9,Not available,Cancer therapy related peptides,Not available,Not available,"Not available","Amidation",Amidation,None,L,2146.56,2145.21,6.92,CDMNQRSTWY,A,C103H160N26O24,2,1,3,2,"Should not be visible by UV spectrophotometry.","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",11.25,134.76,1.300,"9620615++The maculatin peptides from the skin glands of the tree frog Litoria genimaculata: a comparison of the structures and antibacterial activities of maculatin 1.1 and caerin 1.1++Not available++1998##15203252++Host-defence peptides of Australian anurans: structure, mechanism of action and evolutionary significance++10.1016/j.peptides.2004.03.006++2004",Not available,Not available,"Not available",Not available,negative
DCTPep04701,Not available,4410,Not available,Not available,"Caerin 1.9",GLFGVLGSIAKHVLPHVVPVIAEK,24,P81252,Not available,"Litoria chloris",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,2481.02,2479.47,8.61,CDMNQRTWY,V,C118H194N30O28,3,1,4,4,"Should not be visible by UV spectrophotometry.","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",33.66,150.00,1.038,"9516047++Not available++Not available++Not available##18957441++Not available++Not available++Not available##15203252++Not available++Not available++Not available",Not available,Not available,"Not available",Not available,negative
DCTPep01058,Not available,Not available,Not available,Not available,"Ranatuerin-2",GLFLDTLKGAAKDVAGKLEGLKCKITGCKLP,31,Not available,Not available,"Rana catesbeiana",Native peptide,"Human erythrocytes: 0% Hemolysis=20 µg/ml; Sheep erythrocytes: <10% Hemolysis=256 µM","HEK293T cells: IC50>128 µM","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01058,Not available,DCTPep01058.cif,ACP##Tumor active peptide,Not available,Cyclic,"Cys23<--->Cys28","Free",Free,None,L,3188.88,3186.79,9.19,HMNQRSWY,KL,C143H247N37O40S2,3,3,6,9,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.039, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-13.61,107.10,0.187,"34073203++Prediction of Anticancer Peptides with High Efficacy and Low Toxicity by Hybrid Model Based on 3D Structure of Peptides++10.3390/ijms22115630++2021##9784389++Ranatuerins: antimicrobial peptides isolated from the skin of the American bullfrog, Rana catesbeiana++10.1006/bbrc.1998.9362++1998",Not available,Not available,"Not available",Not available,negative
DCTPep02359,Not available,Not available,DBAASPS_4313,Not available,"Palustrin-2ISb (1-29), GL-29",GLWNSIKIAGKKLFVNVLDKIRCKVAGGC,29,G5ELM2,Not available,"Synthetic",Synthetic peptide,"Horse erythrocytes: 10% Hemolysis=5.86 µM; 50% Hemolysis=33.03 µM","Human keratinocytes HaCat: IC50=5.05 µM","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep02359,Not available,DCTPep02359.cif,ACP##Tumor active peptide,Not available,Cyclic,"Cys23<--->Cys29","Free",Free,None,L,3131.83,3129.77,9.90,EHMPQTY,K,C142H240N40O35S2,5,1,6,9,"Ext. coefficient     5625##Abs 0.1% (=1 g/l)   1.796, assuming all pairs of Cys residues form cystines##Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.756, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",5.84,117.59,0.383,"36009917++Targeted Modification and Structure-Activity Study of GL-29, an Analogue of the Antimicrobial Peptide Palustrin-2ISb++10.3390/antibiotics11081048++2022",Not available,Not available,"Not available",Not available,negative
DCTPep02004,Not available,Not available,Not available,Not available,"APETx4",GTTCYCGKTIGIYWFGKYSCPTNRGYTGSCPYFLGICCYPVD,42,C0HL40,Not available,"Anthopleura elegantissima (Green aggregating anemone) (Actinia elegantissima)",Native peptide,"Not available","NIH-3T3: KV10.1 Expression Level (Undetectable); Human epithelial cell line hTERT RPE-1: KV10.1 Expression Level (Moderate)","Not available",Not available,"APETx4 is able to selectively inhibit the human ether-à-go-go channel (hEag1 or KV10.1), which a cancer-relevant voltage-gated potassium channel that is overexpressed in a majority of human tumors.",Anticancer,Not available,DCTPep02004,Not available,DCTPep02004.cif,KV10.1 inhibitor,Not available,Linear,"Not available","Free",Free,None,L,4660.36,4657.04,8.29,AEHMQ,G,C211H301N49O59S6,2,1,3,27,"Ext. coefficient    14815##Abs 0.1% (=1 g/l)   3.179, assuming all pairs of Cys residues form cystines##Ext. coefficient    14440##Abs 0.1% (=1 g/l)   3.098, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",14.16,44.05,0.033,"28902151++APETx4, a Novel Sea Anemone Toxin and a Modulator of the Cancer-Relevant Potassium Channel KV10.1++10.3390/md15090287++2017",Not available,Not available,"Not available",Not available,negative
DCTPep00178,Not available,Not available,Not available,Not available,"Odorranain-C1",GVLGAVKDLLIGAGKSAAQSVLKTLSCKLSNDC,33,Not available,Not available,"Odorrana grahami",Native peptide,"Human erythrocytes: 0% Hemolysis=50 µg/ml; Sheep erythrocytes: <10% Hemolysis=256 µM","Human mast cells: 2.9±1.5% degranulation=50 µg/ml; HEK293T: IC50=48.7 µM","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep00178,Not available,DCTPep00178.cif,ACP##Tumor active peptide,Not available,Cyclic,"Cys27<--->Cys33","Free",Free,None,L,3260.86,3258.77,8.82,EFHMPRWY,L,C140H247N39O45S2,2,2,4,12,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.038, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",19.15,121.21,0.515,"34073203++Prediction of Anticancer Peptides with High Efficacy and Low Toxicity by Hybrid Model Based on 3D Structure of Peptides++10.3390/ijms22115630++2021##17272268++Anti-infection peptidomics of amphibian skin++10.1074/mcp.M600334-MCP200++2007",Not available,Not available,"Not available",Not available,negative
DCTPep02886,Not available,Not available,DBAASPR_17828,Not available,"CEN1 HC",GWFKKTFHKVSHAVKSGIHAGQRGCSALGF,30,D8WN02,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Anti-inflammatory,Not available,DCTPep02886,Not available,DCTPep02886.cif,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,3242.75,3240.69,10.48,DEMNPY,G,C148H225N45O36S1,8,0,8,10,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.696, assuming all pairs of Cys residues form cystines##Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.696, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",15.44,55.33,-0.207,"23237525++Anti-infectious and anti-inflammatory effects of peptide fragments sequentially derived from the antimicrobial peptide centrocin 1 isolated from the green sea urchin, Strongylocentrotus droebachiensis++10.1186/2191-0855-2-67++2012",Not available,Not available,"Not available",Not available,negative
DCTPep00465,Not available,Not available,Not available,Not available,"NRC-16",GWKKWLRKGAKHLGQAAIK,19,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 50% Hemolysis>256 µg/ml","HaCat: Not active up to 50 µM; Zebrafish embryos: >10% Killing=5 µM(52hpf embryos (hpf - hours postfertilization)); Zebrafish embryos: >10% Killing=25 µM(4hpf, 28hpf embryos)","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep00465,Not available,DCTPep00465.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2176.64,2175.29,11.39,CDEFMNPSTVY,K,C102H166N32O21,7,0,7,3,"Ext. coefficient    11000##Abs 0.1% (=1 g/l)   5.054","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",19.19,77.37,-0.853,"21729875++The zebrafish embryo as a tool for screening and characterizing pleurocidin host-defense peptides as anti-cancer agents++10.1242/dmm.007310++2011##23760014++Anti-microbial, anti-biofilm activities and cell selectivity of the NRC-16 peptide derived from witch flounder, Glyptocephalus cynoglossus++10.3390/md11061836++2013",Not available,Not available,"Not available",Not available,negative
DCTPep00014,Not available,Not available,Not available,Not available,"Hepcidin-20",ICIFCCGCCHRSKCGMCCKT,20,Not available,Not available,"Homo sapiens; Pan troglodytes; Pongo pygmaeus; Gorilla gorilla;  Nomascus concolor; Hylobates lar",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep00014,Not available,DCTPep00014.cif,Membrane-targeted,Not available,Cyclic,"Cys2<--->Cys18; Cys5<--->Cys8; Cys6<--->Cys14; Cys9<--->Cys17","Free",Free,None,L,2199.78,2197.83,8.53,ADELNPQVWY,C,C85H143N27O23S9,4,0,4,12,"Ext. coefficient      500##Abs 0.1% (=1 g/l)   0.227, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","20 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",47.77,39.00,0.795,"11113131++Hepcidin, a urinary antimicrobial peptide synthesized in the liver++10.1074/jbc.M008922200++2001",Not available,Not available,"Not available",Not available,negative
DCTPep00156,Not available,1526##1532##1538,DBAASPS_3391,Not available,"LL-37(13-37)",IGKEFKRIVQRIKDFLRNLVPRTES,25,Q1KLX1##P49913,102602726,"LL-37,a series of peptide fragments",Synthetic peptide,"Not available","HBMEC: LC50=38±3 µM","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00156,2FCG,DCTPep00156.cif,ACP##Tumor active peptide##Induce apoptosis,Not available,Linear,"Not available","Free",Amidation,None,L,3043.61,3041.76,10.93,ACHMWY,R,C137H232N42O36,4,3,7,4,"Should not be visible by UV spectrophotometry.","20 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",36.16,101.20,-0.624,"16637646++Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region++10.1021/ja0584875++2005",Not available,Not available,"Not available",Not available,negative
DCTPep02355,Not available,Not available,Not available,Not available,"Pro-apoptotic peptide, PAP",KLAKLAKKLAKLAK,14,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep02355,Not available,DCTPep02355.cif,ACP##Tumor active peptide##Membrane lysis,Not available,Linear,"Not available","Free",Free,None,L,1524.01,1523.06,10.70,CDEFGHIMNPQRSTVWY,K,C72H138N20O15,6,0,6,0,"Should not be visible by UV spectrophotometry.","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-14.97,140.00,-0.071,"26734838++Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy++10.18632/oncotarget.6794++2016",Not available,Not available,"Not available",Not available,negative
DCTPep01374,Not available,Not available,Not available,Not available,"lytic(L)",KLLLKLLKKLLKLLKKK,17,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","PE: IC50>20μM; HEK293T: IC50=11.3±1.1μM; WI-38: IC50=14.4±1.3μM","Interleukin-4 (IL4) Receptor",Not available,"Not available",Anticancer,Not available,DCTPep01374,Not available,DCTPep01374.cif,ACP##Tumor active peptide##Cancer targeted peptides,Not available,Linear,"Not available","Free",Free,None,L,2061.84,2060.53,10.85,ACDEFGHIMNPQRSTVWY,L,C102H197N25O18,8,0,8,0,"Should not be visible by UV spectrophotometry.","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-30.54,206.47,0.176,"Not available++Not available++Not available++Not available",US 2011/0319336 A1,Selective anticancer chimeric peptide.,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",CN102238965A##EP2370107A2##WO2010064207A2##WO2010064207A3,negative
DCTPep00019,Not available,Not available,DBAASPS_696,Not available,"novispirin G-10",KNLRRIIRKGIHIIKKYG,18,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 3% Hemolysis=80 µg/ml","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00019,1HU6,DCTPep00019.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Free,None,L,2206.76,2205.41,11.75,ACDEFMPQSTVW,I,C101H180N34O21,8,0,8,4,"Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.675","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",64.37,130.00,-0.644,"11932493++Impact of single-residue mutations on the structure and function of ovispirin/novispirin antimicrobial peptides++10.1093/protein/15.3.225++2002",Not available,Not available,"Not available",Not available,negative
DCTPep00148,Not available,Not available,Not available,Not available,"lunatusin",KTCENLADTFRGPCFATSNC,20,Not available,Not available,"Phaseolus lunatus",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00148,Not available,DCTPep00148.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2178.44,2176.93,6.05,HIMQVWY,CT,C90H140N26O31S3,0,2,2,10,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.057, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-5.54,29.50,-0.340,"16269344++Lunatusin, a trypsin-stable antimicrobial peptide from lima beans (Phaseolus lunatus L.)++10.1016/j.peptides.2005.03.004++2005",Not available,Not available,"Not available",Not available,negative
DCTPep00136,Not available,Not available,Not available,Not available,"sesquin",KTCENLADTY,10,Not available,Not available,"Ground beans",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,1157.26,1156.51,4.37,FGHIMPQRSVW,T,C48H76N12O19S1,-1,2,1,5,"Ext. coefficient     1490##Abs 0.1% (=1 g/l)   1.288, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   1.288, assuming all Cys residues are reduced","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-14.52,49.00,-0.900,"15949629++Sesquin, a potent defensin-like antimicrobial peptide from ground beans with inhibitory activities toward tumor cells and HIV-1 reverse transcriptase++10.1016/j.peptides.2005.01.003++2005",Not available,Not available,"Not available",Not available,negative
DCTPep00852,Not available,Not available,Not available,Not available,"TP III",KWCFRVCYRGICYRKCR,17,P18252,Not available,"horseshoe crab Limulus polyphemus",Native peptide,"Human red blood cells (hBRC): TP I lysed 20%, at a maximal concentration of 100 µM","HEK 293T: IC50=19.7±1.9 μM; HEF:IC50=14.1±1.2 μM; NHA: IC50=14.1±1.2 μM","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00852,6PIP##6PI3,DCTPep00852.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2240.75,2239.09,9.79,ADEHLMNPQST,CR,C99H154N32O20S4,6,0,6,7,"Ext. coefficient     8730##Abs 0.1% (=1 g/l)   3.896, assuming all pairs of Cys residues form cystines##Ext. coefficient     8480##Abs 0.1% (=1 g/l)   3.784, assuming all Cys residues are reduced","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-20.47,40.00,-0.482,"30486233++Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III++10.3390/md16120466++2018",Not available,Not available,"Not available",Not available,negative
DCTPep00004,Not available,Not available,Not available,Not available,"CA-MA1",KWKLFKKIKFLHSAKKF,17,Not available,Not available,"Ceropin-Magainin hybrid peptides",Synthetic peptide,"Human erythrocytes: Hemolysis 0% (100 μM)","NIH-3T3 fibroblast: IC50>100 μM","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00004,1D9L,DCTPep00004.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,2177.75,2176.34,10.78,CDEGMNPQRTVY,K,C110H173N27O19,8,0,8,1,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.526","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-14.41,74.71,-0.582,"10675500++Effects of the hinge region of cecropin A(1-8)-magainin 2(1-12), a synthetic antimicrobial peptide, on liposomes, bacterial and tumor cells++10.1016/s0005-2736(99)00210-2++2000",Not available,Not available,"Not available",Not available,negative
DCTPep01894,Not available,Not available,DBAASPS_13395,Not available,"LK(8)",LKLKLKLKLKLKLKLK,16,Not available,Not available,"Synthetic",Synthetic peptide,"RBCs: 13%Hemolysis=250 µg/ml","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep01894,Not available,DCTPep01894.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,1948.68,1947.44,10.85,ACDEFGHIMNPQRSTVWY,KL,C96H186N24O17,8,0,8,0,"Should not be visible by UV spectrophotometry.","5.5 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-70.22,195.00,-0.050,"Not available++Not available++Not available++Not available",US7091185B2,Periodic antimicrobial peptides,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",US2005187151A1,negative
DCTPep00494,Not available,5002##5004##5006,Not available,Not available,"LL 37",LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Q1KLX1##P49913,Not available,"Also known human cathelicidin",Synthetic peptide,"Not available","Primary dermal fibroblast: LC50=26 at 100 µM","Not available",Not available,"Not available",Anticancer; Antimicrobial,Not available,DCTPep00494,2K6O,DCTPep00494.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,4493.32,4490.58,10.61,ACHMWY,K,C205H340N60O53,6,5,11,6,"Should not be visible by UV spectrophotometry.","5.5 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",23.34,89.46,-0.724,"24587350++Learning from host-defense peptides: cationic, amphipathic peptoids with potent anticancer activity++10.1371/journal.pone.0090397++2014",Not available,Not available,"Not available",Not available,negative
DCTPep00269,Not available,Not available,Not available,Not available,"DI",LTFEHYWAQLTS,12,Not available,Not available,"E3 ubiquitin-protein ligase",Synthetic peptide,"Not available","Not available","MDM2",Not available,"Inhibits MDM2-p53 Interaction",Anticancer; Antitumor,Not available,Not available,Not available,Not available,ACP##Tumor active peptide##Cancer targeted peptides##Affect cell cycle,Not available,Linear,"Not available","Free",Free,None,L,1495.65,1494.71,5.24,CDGIKMNPRV,LT,C71H98N16O20,0,1,1,4,"Ext. coefficient     6990##Abs 0.1% (=1 g/l)   4.674","5.5 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",28.62,73.33,-0.200,"21423613++mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction++10.1371/journal.pone.0017898++2011",Not available,Not available,"Not available",Not available,negative
DCTPep05902,Not available,Not available,Not available,Not available,"ATSP-3848",LTFEHYWAQLTS,12,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","MDM2, MDMX",MDM2: Ki=14.6 nM; MDMX: Ki=47.4 nM,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer targeted peptides##Induce apoptosis##MDM2/MDMX Inhibitor,Not available,Linear,"Not available","Acetylation",Amidation,None,L,1495.65,1494.71,5.24,CDGIKMNPRV,LT,C71H98N16O20,0,1,1,4,"Ext. coefficient     6990##Abs 0.1% (=1 g/l)   4.674","5.5 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",28.62,73.33,-0.200,"23946421++Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy++10.1073/pnas.1303002110++2013",Not available,Not available,"Not available",Not available,negative
DCTPep00144,Not available,Not available,DBAASPR_2979,Not available,"Cherimolacyclopeptide E",PGLGFY,6,P85003,Not available,"Annona cherimola (Custard apple) (Cherimoya)",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Cyclic,"NCB: Pro1<--->Tyr6","Free",Free,None,L,652.75,652.32,5.95,ACDEHIKMNQRSTVW,G,C33H44N6O8,0,0,0,3,"Ext. coefficient     1490##Abs 0.1% (=1 g/l)   2.283",">20 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##? (Escherichia coli, in vivo).",62.67,65.00,0.483,"16040066++Two cyclopeptides from the seeds of Annona cherimola++10.1016/j.phytochem.2005.06.011++2005",Not available,Not available,"Not available",Not available,negative
DCTPep02173,Not available,Not available,DBAASPR_2980,Not available,"Cherimolacyclopeptide F",PGMGIYLPM,9,P85002,Not available,"Annona cherimola",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Cyclic,"NCB: Pro1<--->Met9","Free",Free,None,L,978.23,977.47,5.95,ACDEFHKNQRSTVW,GMP,C45H71N9O11S2,0,0,0,3,"Ext. coefficient     1490##Abs 0.1% (=1 g/l)   1.523",">20 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##? (Escherichia coli, in vivo).",12.48,86.67,0.756,"16040066++Two cyclopeptides from the seeds of Annona cherimola++10.1016/j.phytochem.2005.06.011++2005",Not available,Not available,"Not available",Not available,negative
DCTPep00271,Not available,Not available,Not available,Not available,"P5317-28",QETFSDLWKLLP,12,Not available,Not available,"E3 ubiquitin-protein ligase",Synthetic peptide,"Not available","Not available","MDM2",Not available,"Inhibits MDM2-p53 Interaction",Anticancer; Antitumor,Not available,Not available,Not available,Not available,ACP##Tumor active peptide##Cancer targeted peptides##Affect cell cycle,Not available,Linear,"Not available","Free",Free,None,L,1476.69,1475.77,4.37,ACGHIMNRVY,L,C70H105N15O20,-1,2,1,2,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.725","0.8 hours (mammalian reticulocytes, in vitro).##10 min (yeast, in vivo).##10 hours (Escherichia coli, in vivo).",64.21,97.50,-0.350,"21423613++mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction++10.1371/journal.pone.0017898++2011",Not available,Not available,"Not available",Not available,negative
DCTPep00855,Not available,Not available,Not available,Not available,"PM II",RRWCFRVCYKGFCYRKCR,18,P14216,Not available,"horseshoe crab Limulus polyphemus",Native peptide,"Human red blood cells (hBRC): only ~30%, even at the maximal concentration of 100 µM","HEK 293T: IC50=11.3±1.6 μM; HEF: IC50=9.7±0.2 μM; NHA: IC50=18.3±1.4 μM","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00855,Not available,DCTPep00855.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2430.96,2429.18,10.10,ADEHILMNPQST,R,C108H164N36O21S4,7,0,7,7,"Ext. coefficient     8730##Abs 0.1% (=1 g/l)   3.591, assuming all pairs of Cys residues form cystines##Ext. coefficient     8480##Abs 0.1% (=1 g/l)   3.488, assuming all Cys residues are reduced","1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",58.98,16.11,-0.800,"30486233++Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III++10.3390/md16120466++2018",Not available,Not available,"Not available",Not available,negative
DCTPep00947,Not available,Not available,Not available,Not available,"Combi-1",RRWWRF,6,Not available,Not available,"porcine cathelicidin peptide",Synthetic peptide,"RBC: IC50 ≥ 65 µM","PBMC: IC50 ≥ 65 µM","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,1006.18,1005.54,12.30,ACDEGHIKLMNPQSTVY,R,C49H67N17O7,3,0,3,0,"Ext. coefficient    11000##Abs 0.1% (=1 g/l)  10.932","1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",199.27,0.00,-2.083,"32126228++Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin++10.1016/j.bbamem.2020.183228++2020",Not available,Not available,"Not available",Not available,negative
DCTPep00857,Not available,Not available,Not available,Not available,"TP II",RWCFRVCYRGICYRKCR,17,P14214,Not available,"horseshoe crab Limulus polyphemus",Native peptide,"Human red blood cells (hBRC): TP I lysed 33%, at a maximal concentration of 100 µM","HEK 293T: IC50=24.6±1.7 μM; HEF: IC50=17.7±1.2 μM; NHA: IC50=29.4±1.7 μM","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00857,6PI2##6PIO,DCTPep00857.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2268.77,2267.1,9.93,ADEHLMNPQST,R,C99H154N34O20S4,6,0,6,7,"Ext. coefficient     8730##Abs 0.1% (=1 g/l)   3.848, assuming all pairs of Cys residues form cystines##Ext. coefficient     8480##Abs 0.1% (=1 g/l)   3.738, assuming all Cys residues are reduced","1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",13.22,40.00,-0.518,"30486233++Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III++10.3390/md16120466++2018",Not available,Not available,"Not available",Not available,negative
DCTPep04461,Not available,Not available,20021,Not available,"Latarcin-3a, Ltc-3a",SWKSMAKKLKEYMEKLKQRA,20,Q1ELU3,Not available,"Animalia",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,2484.02,2482.36,10.12,CDFGHINPTV,K,C111H187N31O29S2,5,2,7,3,"Ext. coefficient     6990##Abs 0.1% (=1 g/l)   2.814","1.9 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",32.5,49.00,-1.360,"36212827++First generation of multifunctional peptides derived from latarcin-3a from Lachesana tarabaevi spider toxin++10.3389/fmicb.2022.965621++2022",Not available,Not available,"Not available",Not available,negative
DCTPep02687,Not available,Not available,DBAASPR_13548,Not available,"Pyrrhocoricin",VDKGSYLPRPTPPRPIYNRN,20,P37362,Not available,"Pyrrhocoris apterus",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep02687,Not available,DCTPep02687.cif,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,2340.67,2339.25,10.27,ACEFHMQW,P,C105H166N32O29,3,1,4,7,"Ext. coefficient     2980##Abs 0.1% (=1 g/l)   1.273","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",30.65,53.50,-1.395,"31209863++Identification and elucidation of proline-rich antimicrobial peptides with enhanced potency and delivery++10.1002/bit.27092++2019",Not available,Not available,"Not available",Not available,negative
DCTPep00375,Not available,Not available,Not available,Not available,"LL-III",VNWKKILGKIIKVVK,15,Not available,Not available,"Lasioglossin III and its analogs",Native peptide,"Rat erythrocytes: IC50>200 μM","HUVEC: IC50=15±4 μM","Not available",Not available,"Not available",Anticancer; Antimicrobial; Antifungal,Not available,DCTPep00375,Not available,DCTPep00375.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,1766.29,1765.17,10.60,ACDEFHMPQRSTY,K,C86H152N22O17,5,0,5,2,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.114","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-14.96,162.00,0.373,"22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012",Not available,Not available,"Not available",Not available,negative
DCTPep00378,Not available,Not available,Not available,Not available,"LL-III/8",VNWKKILGKIIKVVK,15,Not available,Not available,"Synthetic",Synthetic peptide,"Rat erythrocytes: IC50>200 μM","HUVEC: IC50=80+ μM","Not available",Not available,"Not available",Anticancer; Antimicrobial; Antifungal,Not available,DCTPep00378,Not available,DCTPep00378.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Free,None,L,1766.29,1765.17,10.60,ACDEFHMPQRSTY,K,C86H152N22O17,5,0,5,2,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.114","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-14.96,162.00,0.373,"22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012",Not available,Not available,"Not available",Not available,negative
DCTPep00379,Not available,Not available,Not available,Not available,"LL-III/9",VNWKKILGKIIKVVK,15,Not available,Not available,"Synthetic",Synthetic peptide,"Rat erythrocytes: IC50>200 μM","HUVEC: IC50=30±2 μM","Not available",Not available,"Not available",Anticancer; Antimicrobial; Antifungal,Not available,DCTPep00379,Not available,DCTPep00379.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Methylester (OMe),None,L,1766.29,1765.17,10.60,ACDEFHMPQRSTY,K,C86H152N22O17,5,0,5,2,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.114","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-14.96,162.00,0.373,"22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012",Not available,Not available,"Not available",Not available,negative
DCTPep00381,Not available,Not available,Not available,Not available,"LL-III/3",VNWKKILKKIIKVVK,15,Not available,Not available,"Synthetic",Synthetic peptide,"Rat erythrocytes: IC50>200 μM","HUVEC: IC50=20±1 μM","Not available",Not available,"Not available",Anticancer; Antimicrobial; Antifungal,Not available,DCTPep00381,Not available,DCTPep00381.cif,Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,1837.41,1836.24,10.70,ACDEFGHMPQRSTY,K,C90H161N23O17,6,0,6,1,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.993","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-14.96,162.00,0.140,"22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012",Not available,Not available,"Not available",Not available,negative
DCTPep03523,Not available,Not available,6227,Not available,"Carnobacteriocin B2",VNYGNGVSCSKTKCSVNWGQAFQERYTAGINSFVSGVASGAGSIGRRP,48,P38580,Not available,"Bacteria",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep03523,1CW5,DCTPep03523.cif,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,4969.5,4966.4,9.70,DHLM,G,C213H332N66O68S2,4,1,5,25,"Ext. coefficient     8605##Abs 0.1% (=1 g/l)   1.732, assuming all pairs of Cys residues form cystines##Ext. coefficient     8480##Abs 0.1% (=1 g/l)   1.706, assuming all Cys residues are reduced","100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",18.68,54.79,-0.277,"19271288++Interactions between two carnobacteriocins Cbn BM1 and Cbn B2 from Carnobacterium maltaromaticum CP5 on target bacteria and Caco-2 cells++Not available++2009",Not available,Not available,"Not available",Not available,negative
DCTPep02603,Not available,Not available,Not available,Not available,"NRC-02",WLRRIGKGVKIIGGAALDHL,20,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 50% Hemolysis>256 µg/ml","Zebrafish embryos: No killing","Not available",Not available,"Not available",Anticancer,Not available,DCTPep02603,Not available,DCTPep02603.cif,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,2173.64,2172.3,11.00,CEFMNPQSTY,G,C100H169N31O23,4,1,5,4,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.530","2.8 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",41.69,141.50,0.335,"21729875++The zebrafish embryo as a tool for screening and characterizing pleurocidin host-defense peptides as anti-cancer agents++10.1242/dmm.007310++2011",Not available,Not available,"Not available",Not available,negative
DCTPep01101,Not available,Not available,Not available,Not available,"P17",YQEPVLGPVRGPFPIIV,17,Q9TSI0##P02666,Not available,"Synbiotic yoghurt",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep01101,Not available,DCTPep01101.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,1881.25,1880.06,6.00,ACDHKMNSTW,P,C91H141N21O22,0,1,1,3,"Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.792","2.8 hours (mammalian reticulocytes, in vitro).##10 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",67.4,120.00,0.482,"Not available++Antioxidant peptides isolated from synbiotic yoghurt exhibit antiproliferative activities against HT-29 colon cancer cells++10.1016/j.idairyj.2016.08.003++2016",Not available,Not available,"Not available",Not available,negative
DCTPep03982,Not available,Not available,15142,Not available,"Z10",AAKKWAKAKKWAKAKKWAKAA,21,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,2369.93,2368.44,10.90,CDEFGHILMNPQRSTVY,AK,C114H185N33O22,9,0,9,0,"Ext. coefficient    16500##Abs 0.1% (=1 g/l)   6.962","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-11.95,42.86,-1.029,"22057278++Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity++Not available++2012",Not available,Not available,"Not available",Not available,positive
DCTPep00324,Not available,Not available,Not available,Not available,"Z10",AAKKWAKAKWAKAKKWAKAA,20,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00324,Not available,DCTPep00324.cif,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,2241.76,2240.34,10.85,CDEFGHILMNPQRSTVY,A,C108H173N31O21,8,0,8,0,"Ext. coefficient    16500##Abs 0.1% (=1 g/l)   7.360","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-13.04,45.00,-0.885,"22057278++Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity++10.1074/jbc.M111.279281++2012",Not available,Not available,"Not available",Not available,positive
DCTPep04818,Not available,Not available,Not available,Not available,"Tetrastatin-3",AAPFLECQGRQGTCHFFAN,19,Not available,Not available,"Homo sapiens (α4 CIV)",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Not available,"Not available","Free",Free,None,L,2097.35,2095.94,6.77,DIKMSVWY,AF,C92H133N27O26S2,1,1,2,6,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.060, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",66.27,36.32,-0.116,"18780781++A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells++10.1073/pnas.0803241105++2008",Not available,Not available,"Not available",Not available,positive
DCTPep01936,Not available,Not available,DBAASPS_12678,Not available,"FGR (7-22)-X13, FGF-X13",AAVALLPAVLLALLAPMPFSTGKRIMLGE,29,P08620,Not available,"Synthetic",Synthetic peptide,"Not available","HEK293: Not active up to 100 µM; HFF: Not active up to 100 µM","Not available",Not available,"Not available",Anticancer,Not available,DCTPep01936,Not available,DCTPep01936.cif,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,2964.7,2962.71,8.79,CDHNQWY,L,C138H235N33O34S2,1,1,2,4,"Should not be visible by UV spectrophotometry.","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",51.56,148.28,1.307,"26734838++Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy++10.18632/oncotarget.6794++2016",Not available,Not available,"Not available",Not available,positive
DCTPep01944,Not available,Not available,DBAASPS_12686,Not available,"FGR (7-22)-HEXIM1 (147-164)[K6I,H7L][R8,9A], FGF-BR(ILAA)",AAVALLPAVLLALLAPQLGKKILAARPSKKKRHW,34,O94992##P08620,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep01944,Not available,DCTPep01944.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,3643.56,3641.29,12.04,CDEFMNTY,AL,C172H297N49O37,8,0,8,2,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.510","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",58.77,143.82,0.459,"26734838++Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy++10.18632/oncotarget.6794++2016",Not available,Not available,"Not available",Not available,positive
DCTPep01937,Not available,Not available,DBAASPS_12679,Not available,"FGR (7-22)-HEXIM1 (147-164), FGF-BR",AAVALLPAVLLALLAPQLGKKKHRRRPSKKKRHW,34,P08620##O94992,Not available,"Synthetic",Synthetic peptide,"Not available","HEK293: 30%Killing=10 µM; HFF: 20%Killing=10 µM; 90%Killing=50 µM","Not available",Not available,"Not available",Anticancer,Not available,DCTPep01937,Not available,DCTPep01937.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,3852.77,3850.4,12.49,CDEFIMNTY,L,C178H308N58O37,12,0,12,2,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.428","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",89.3,115.00,-0.365,"26734838++Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy++10.18632/oncotarget.6794++2016",Not available,Not available,"Not available",Not available,positive
DCTPep01943,Not available,Not available,DBAASPS_12685,Not available,"FGR (7-22)-HEXIM1 (147-164)[K4,5,6,13,14,15R], FGF-BR(RRR12)",AAVALLPAVLLALLAPQLGRRRHRRRPSRRRRHW,34,O94992##P08620,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep01943,Not available,DCTPep01943.cif,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,4020.85,4018.44,12.95,CDEFIKMNTY,R,C178H308N70O37,12,0,12,2,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.368","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",177.77,115.00,-0.471,"26734838++Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy++10.18632/oncotarget.6794++2016",Not available,Not available,"Not available",Not available,positive
DCTPep00129,Not available,Not available,Not available,Not available,"hP4",AAVPIVNLKDELLFPSWEALFSGSE,25,P39060,Not available,"Human endostatin peptides",Native peptide,"Not available","Not available","α5β1 integrin, metalloproteinases",Not available,"Inhibition of endothelial cell proliferation, migration, and tube formation",Anticancer; Antiangiogenesis,Not available,DCTPep00129,Not available,DCTPep00129.cif,Cancer targeted peptides,Not available,Linear,"Not available","Free",Free,None,L,2733.11,2731.41,4.00,CHMQRTY,L,C128H194N28O38,-3,4,1,5,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.012","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",33.62,113.20,0.432,"15867360++A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity++10.1158/0008-5472.CAN-04-1833++2005",Not available,Not available,"Not available",Not available,positive
DCTPep00325,Not available,Not available,Not available,Not available,"Z9",AAWKWAWAKKWAKAKKWAKAA,21,Not available,Not available,"Synthetic",Synthetic peptide,"MRC-5: EC58=14 μM","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00325,Not available,DCTPep00325.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2486.01,2484.41,10.78,CDEFGHILMNPQRSTVY,A,C124H181N33O22,7,0,7,0,"Ext. coefficient    27500##Abs 0.1% (=1 g/l)  11.062","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-19.1,42.86,-0.743,"22057278++Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity++10.1074/jbc.M111.279281++2012",Not available,Not available,"Not available",Not available,positive
DCTPep00233,Not available,Not available,Not available,Not available,"AP",ACDCRGDCFCGGGGIVRRADRAAVP,25,Not available,Not available,"Endostatin derived Synthetic",Synthetic peptide,"Not available","Not available","integrin αvβ3",Not available,"Not available",Anticancer,Not available,DCTPep00233,Not available,DCTPep00233.cif,ACP##Tumor active peptide##Cancer targeted peptides,Not available,Linear,"Not available","Free",Free,None,L,2525.88,2524.13,7.93,EHKLMNQSTWY,G,C100H165N37O32S4,1,3,4,9,"Ext. coefficient      250##Abs 0.1% (=1 g/l)   0.099, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",63.7,54.80,0.032,"20515045++Effect of RGD-4C Position is More Important Than Disulfide Bonds on Antiangiogenic Activity of RGD-4C Modified Endostatin Derived Synthetic Polypeptide++10.1021/bc900292y++2010",Not available,Not available,"Not available",Not available,positive
DCTPep00234,Not available,Not available,Not available,Not available,"AP(O)",ACDCRGDCFCGGGGIVRRADRAAVP,25,Not available,Not available,"Endostatin derived Synthetic",Synthetic peptide,"Not available","Not available","integrin αvβ3",Not available,"Not available",Anticancer,Not available,DCTPep00234,Not available,DCTPep00234.cif,ACP##Tumor active peptide##Cancer targeted peptides,Not available,Cyclic,"Cys2 <--> Cys10, Cys4 <--> Cys8","Free",Free,None,L,2525.88,2524.13,7.93,EHKLMNQSTWY,G,C100H165N37O32S4,1,3,4,9,"Ext. coefficient      250##Abs 0.1% (=1 g/l)   0.099, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",63.7,54.80,0.032,"20515045++Effect of RGD-4C Position is More Important Than Disulfide Bonds on Antiangiogenic Activity of RGD-4C Modified Endostatin Derived Synthetic Polypeptide++10.1021/bc900292y++2010",Not available,Not available,"Not available",Not available,positive
DCTPep02373,Not available,Not available,DBAASPR_4467,Not available,"Psalmopeotoxin I, PcFK1",ACGILHDNCVYVPAQNPCCRGLQCRYGKCLVQV,33,P0C201,Not available,"Psalmopoeus cambridgei",Native peptide,"Human erythrocytes: Not active at 10 µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep02373,Not available,DCTPep02373.cif,Cancer therapy related peptides,Not available,Cyclic,"Cys2<--->Cys19; Cys9<--->Cys24; Cys18<--->Cys29","Free",Free,None,L,3625.29,3622.69,8.35,EFMSTW,C,C153H247N47O43S6,3,1,4,13,"Ext. coefficient     3355##Abs 0.1% (=1 g/l)   0.925, assuming all pairs of Cys residues form cystines##Ext. coefficient     2980##Abs 0.1% (=1 g/l)   0.822, assuming all Cys residues are reduced","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",30.49,88.48,0.218,"15304333++Isolation and characterization of Psalmopeotoxin I and II: two novel antimalarial peptides from the venom of the tarantula Psalmopoeus cambridgei++10.1016/j.febslet.2004.07.019++2004",Not available,Not available,"Not available",Not available,positive
DCTPep04705,DRAMP02902,Not available,Not available,Not available,"L-amino-acid oxidase (LAAO, LAO; BpirLAAO-I; reptilia, animals)",ADDKNPLEEFRETNYEVFLEIAKNGLKATSNPKRVVIVGAGMAGLSAAY,49,P0C2D1,Not available,"Bothrops pirajai",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,5299,5295.72,5.15,CHQW,A,C235H375N63O74S1,-1,7,6,14,"Ext. coefficient     2980##Abs 0.1% (=1 g/l)   0.562","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",10.31,85.71,-0.253,"16809041++Biochemical and functional characterization of an L-amino acid oxidase isolated from Bothrops pirajai snake venom++10.1016/j.bmc.2006.06.025++2006",Not available,Not available,"Not available",Not available,positive
DCTPep03658,Not available,Not available,10358,Not available,"TistH",ADMDFTGIAESIIKKIKETNAKPPA,25,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,2689.12,2687.42,6.26,CHLQRVWY,AIK,C119H198N30O38S1,0,4,4,5,"Should not be visible by UV spectrophotometry.","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",0.29,78.40,-0.360,"27267248++Characterization of TistH, a multifunctional peptide from the scorpion Tityus stigmurus: Structure, cytotoxicity and antimicrobial activity++Not available++2016",Not available,Not available,"Not available",Not available,positive
DCTPep02842,Not available,Not available,DBAASPS_16955,Not available,"LHH1",AFALIAGALYRIFHRR,16,Q036I7,Not available,"Lactobacillus casei HZ1",Synthetic peptide,"Goat erythrocytes: HC50=187.2 µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep02842,Not available,DCTPep02842.cif,ACP##Tumor active peptide##Membrane lysis##Induce apoptosis,Not available,Linear,"Not available","Free",Free,None,L,1875.25,1874.08,11.71,CDEKMNPQSTVW,A,C89H139N27O18,4,0,4,2,"Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.795","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",29.3,122.50,0.688,"33175275++LHH1, a novel antimicrobial peptide with anti-cancer cell activity identified from Lactobacillus casei HZ1++10.1186/s13568-020-01139-8++2020",Not available,Not available,"Not available",Not available,positive
DCTPep00340,Not available,Not available,Not available,Not available,"MAC1/2",AFGMALKLLKKVL,13,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: IC50>200 μM","HUVEC: IC50=30±4 μM","Not available",Not available,"Not available",Anticancer; Antimicrobial; Antifungal,Not available,DCTPep00340,Not available,DCTPep00340.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,1431.89,1430.9,10.30,CDEHINPQRSTWY,L,C69H122N16O14S1,3,0,3,1,"Should not be visible by UV spectrophotometry.","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-7.4,157.69,1.200,"22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012",Not available,Not available,"Not available",Not available,positive
DCTPep03963,Not available,Not available,15043,Not available,"AGG-KR12-GAGG-KR12-G [Q8,24K; D12,28K]",AGGKRIVKRIKKFLRGAGGKRIVKRIKKFLRG,32,P49913,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,3636.58,3634.36,12.71,CDEHMNPQSTWY,K,C166H300N58O33,14,0,14,6,"Should not be visible by UV spectrophotometry.","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",44.51,97.50,-0.544,"32153522++Backbone Cyclization and Dimerization of LL-37-Derived Peptides Enhance Antimicrobial Activity and Proteolytic Stability++Not available++2020",Not available,Not available,"Not available",Not available,positive
DCTPep03962,Not available,Not available,15040,Not available,"AGG-KR12-GAGG-KR12-G",AGGKRIVQRIKDFLRGAGGKRIVQRIKDFLRG,32,P49913,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,3610.32,3608.15,12.01,CEHMNPSTWY,GR,C160H278N56O39,8,2,10,6,"Should not be visible by UV spectrophotometry.","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",21.22,97.50,-0.494,"32153522++Backbone Cyclization and Dimerization of LL-37-Derived Peptides Enhance Antimicrobial Activity and Proteolytic Stability++Not available++2020",Not available,Not available,"Not available",Not available,positive
DCTPep01305,Not available,Not available,Not available,Not available,"Sequence 12 from Patent US 20100279918",AGYLLGKINLKALAALAKKIL,21,Not available,Not available,"Synthetic construct",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep01305,1SMZ,DCTPep01305.cif,ACP,Not available,Not available,"Not available","Not available",Not available,None,L,2182.76,2181.4,10.18,CDEFHMPQRSTVW,L,C104H184N26O24,4,0,4,4,"Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.683","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-1.52,172.38,0.933,"Not available++Not available++Not available++Not available",US 2010/0279918 A1,Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.,"Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status:   Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;",DE602007011901D1##EP1991586A1##EP1991586B1##WO2007108749A1##WO2007108749A8,positive
DCTPep00096,Not available,Not available,Not available,Not available,"Magainin A",AIGKFLHSAKKFGKAFVGEIMNS,23,C0HKN6##P11006,Not available,"African clawed frog Xenopus laevis skin",Native peptide,"Detectable but low hemolytic activity","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep00096,Not available,DCTPep00096.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Beta-alanine",Amidation,None,L,2480.95,2479.34,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Not Applicable","Not Applicable",Not Applicable,Not Applicable,Not Applicable,"1319823++Antitumor activity of magainin analogues against human lung cancer cell lines++Not available++1992##2285300++Magainin analogs effective against pathogenic protozoa++10.1128/AAC.34.9.1824++1990##1708887++Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation++10.1073/pnas.88.9.3792++1990",Not available,Not available,"Not available",Not available,positive
DCTPep01981,Not available,Not available,DBAASPS_14055,Not available,"A-I",AIIKKIIKKIIKKI,14,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 5% Hemolysis=300 µM; Human erythrocytes: 10% Hemolysis=500 µM","Human chondrocytes-articular cells Hca: 25% Killing=40 µM","Not available",Not available,"Not available",Anticancer,Not available,DCTPep01981,Not available,DCTPep01981.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,1650.25,1649.21,10.70,CDEFGHLMNPQRSTVWY,I,C81H156N20O15,6,0,6,0,"Should not be visible by UV spectrophotometry.","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-27.1,202.14,0.707,"27644109++Surface Physical Activity and Hydrophobicity of Designed Helical Peptide Amphiphiles Control Their Bioactivity and Cell Selectivity++10.1021/acsami.6b08297++2016",Not available,Not available,"Not available",Not available,positive
DCTPep03522,Not available,Not available,6216,Not available,"Carnobacteriocin BM1",AISYGNGVYCNKEKCWVNKAENKQAITGIVIGGWASSLAGMGH,43,P38579,Not available,"Bacteria",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep03522,Not available,DCTPep03522.cif,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,4527.17,4524.21,8.76,DFPR,G,C199H310N56O59S3,3,2,5,19,"Ext. coefficient    14105##Abs 0.1% (=1 g/l)   3.116, assuming all pairs of Cys residues form cystines##Ext. coefficient    13980##Abs 0.1% (=1 g/l)   3.088, assuming all Cys residues are reduced","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",26.93,77.21,-0.077,"19271288++Interactions between two carnobacteriocins Cbn BM1 and Cbn B2 from Carnobacterium maltaromaticum CP5 on target bacteria and Caco-2 cells++Not available++2009",Not available,Not available,"Not available",Not available,positive
DCTPep04739,DRAMP04076,Not available,892,Not available,"50S ribosomal protein L1 HP(2-20) [D18W]",AKKVFKRLEKLFSKIQNWK,19,P56029,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,1P0J,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,2391.93,2390.43,10.68,CDGHMPTY,K,C114H187N31O25,6,1,7,2,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.299","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-0.14,82.11,-0.863,"17961502++Amphipathic alpha-helical peptide, HP (2-20), and its analogues derived from Helicobacter pylori: pore formation mechanism in various lipid compositions++10.1016/j.bbamem.2007.09.020++2008##16255716++Not available++Not available++Not available##12147359++Not available++Not available++Not available",Not available,Not available,"Not available",Not available,positive
DCTPep04740,DRAMP04077,Not available,893,Not available,"50S ribosomal protein L1 HP(2-20) [Q16W]",AKKVFKRLEKLFSKIWNDK,19,P56029,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,1P0L,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,2378.89,2377.4,10.30,CGHMPQTY,K,C113H184N30O26,5,2,7,2,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.312","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",7.34,82.11,-0.863,"17961502++Amphipathic alpha-helical peptide, HP (2-20), and its analogues derived from Helicobacter pylori: pore formation mechanism in various lipid compositions++10.1016/j.bbamem.2007.09.020++2008##16255716++Not available++Not available++Not available##12147359++Not available++Not available++Not available",Not available,Not available,"Not available",Not available,positive
DCTPep04741,DRAMP04078,Not available,894,Not available,"50S ribosomal protein L1 HP(2-20) [Q16W][D18W]",AKKVFKRLEKLFSKIWNWK,19,P56029,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,1P0O,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,2450.01,2448.45,10.68,CDGHMPQTY,K,C120H189N31O24,6,1,7,2,"Ext. coefficient    11000##Abs 0.1% (=1 g/l)   4.490","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",6.35,82.11,-0.726,"17961502++Amphipathic alpha-helical peptide, HP (2-20), and its analogues derived from Helicobacter pylori: pore formation mechanism in various lipid compositions++10.1016/j.bbamem.2007.09.020++2008##16255716++Not available++Not available++Not available##12147359++Not available++Not available++Not available",Not available,Not available,"Not available",Not available,positive
DCTPep04742,DRAMP04079,Not available,895,Not available,"50S ribosomal protein L1 HP(2-20) [L11S]",AKKVFKRLEKSFSKIQNDK,19,P56029,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,1P5K,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,2294.73,2293.33,10.30,CGHMPTWY,K,C104H176N30O28,5,2,7,3,"Should not be visible by UV spectrophotometry.","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",5.32,61.58,-1.242,"17961502++Amphipathic alpha-helical peptide, HP (2-20), and its analogues derived from Helicobacter pylori: pore formation mechanism in various lipid compositions++10.1016/j.bbamem.2007.09.020++2008##16255716++Not available++Not available++Not available##12147359++Not available++Not available++Not available",Not available,Not available,"Not available",Not available,positive
DCTPep04743,DRAMP04080,Not available,896,Not available,"50S ribosomal protein L1 HP(2-20) [F5S]",AKKVSKRLEKLFSKIQNDK,19,P56029,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,1P5L,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,2260.71,2259.34,10.30,CGHMPTWY,K,C101H178N30O28,5,2,7,3,"Should not be visible by UV spectrophotometry.","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",8.76,82.11,-1.189,"17961502++Amphipathic alpha-helical peptide, HP (2-20), and its analogues derived from Helicobacter pylori: pore formation mechanism in various lipid compositions++10.1016/j.bbamem.2007.09.020++2008##16255716++Not available++Not available++Not available##12147359++Not available++Not available++Not available",Not available,Not available,"Not available",Not available,positive
DCTPep01945,Not available,Not available,DBAASPS_13109,Not available,"1",ALFGILKKAFGKILTIFAGLPGVV,24,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep01945,Not available,DCTPep01945.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,2474.11,2472.52,10.30,CDEHMNQRSWY,GL,C123H201N27O26,3,0,3,5,"Should not be visible by UV spectrophotometry.","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",19.51,150.42,1.471,"30953170++De novo design of anticancer peptides by ensemble artificial neural networks++10.1007/s00894-019-4007-6++2019",Not available,Not available,"Not available",Not available,positive
DCTPep00175,Not available,Not available,Not available,Not available,"Z44",ALSKALSKALSKALSKALSKALSK,24,Not available,Not available,"Xenopus laevis",Synthetic peptide,"Not available","Not available","Not available",Not available,"magainin 2 and synthetic analogues can rapidly and irreversibly lyse hematopoietic tumor and solid tumor",Anticancer; Antimicrobial,Not available,DCTPep00175,Not available,DCTPep00175.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2414.96,2413.5,10.70,CDEFGHIMNPQRTVWY,AKLS,C108H200N30O31,6,0,6,6,"Should not be visible by UV spectrophotometry.","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",9.58,122.50,0.225,"1708887++Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation++10.1073/pnas.88.9.3792++1990##2285300++Magainin analogs effective against pathogenic protozoa++10.1128/AAC.34.9.1824++1990",Not available,Not available,"Not available",Not available,positive
DCTPep00485,Not available,Not available,Not available,Not available,"Dermaseptin S4 [M4D][N20D]",ALWDTLLKKVLKAAAKAALDAVLVGANA,28,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 50% Hemolysis=5±1 µM","Vero cells: 50% Cytotoxicity =17.75 µM","Not available",Not available,"Not available",Anticancer; Antibacterial; Antiviral,Not available,DCTPep00485,Not available,DCTPep00485.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2835.43,2833.68,9.53,CEFHIMPQRSY,A,C131H224N34O35,2,2,4,3,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.940","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-2.43,146.79,0.839,"24492362++In vitro activities of dermaseptins K4S4 and K4K20S4 against Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa planktonic growth and biofilm formation++10.1128/AAC.02142-13++2014##10660589++Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity++10.1074/jbc.275.6.4230++2000##23161023++In vitro antiviral activity of dermaseptin S(4) and derivatives from amphibian skin against herpes simplex virus type 2++10.1002/jmv.23450++2013",Not available,Not available,"Not available",Not available,positive
DCTPep00828,Not available,Not available,Not available,Not available,"DPS3",ALWKDILKNAGKAALNEINQIVQ,23,P84924,Not available,"skin secretion of Phyllomedusa sauvagii",Native peptide,"Horse blood cells: HC50=138.1 μM","HMEC-1: IC50=132.10 μM","Not available",Not available,"Not available",Anticancer; Antitumor; Antimicrobial,Not available,DCTPep00828,Not available,DCTPep00828.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2550.98,2549.43,8.54,CFHMPRSTY,A,C115H192N32O33,1,2,3,4,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.156","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",22.26,131.74,-0.052,"30087268++Biological Activities of Cationicity-Enhanced and Hydrophobicity-Optimized Analogues of an Antimicrobial Peptide, Dermaseptin-PS3, from the Skin Secretion of Phyllomedusa sauvagii++10.3390/toxins10080320++2018",Not available,Not available,"Not available",Not available,positive
DCTPep00829,Not available,Not available,Not available,Not available,"L10, 11-DPS3",ALWKDILKNLLKAALNEINQIVQ,23,Not available,Not available,"skin secretion of Phyllomedusa sauvagii",Native peptide,"Horse blood cells: HC50=3.44 μM","HMEC-1: IC50=8.76 μM","Not available",Not available,"Not available",Anticancer; Antitumor; Antimicrobial,Not available,DCTPep00829,Not available,DCTPep00829.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2649.17,2647.54,8.54,CFGHMPRSTY,L,C122H206N32O33,1,2,3,3,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.076","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",22.26,161.30,0.217,"30087268++Biological Activities of Cationicity-Enhanced and Hydrophobicity-Optimized Analogues of an Antimicrobial Peptide, Dermaseptin-PS3, from the Skin Secretion of Phyllomedusa sauvagii++10.3390/toxins10080320++2018",Not available,Not available,"Not available",Not available,positive
DCTPep00800,Not available,Not available,Not available,Not available,"Dermaseptin-PH",ALWKEVLKNAGKAALNEINNLVQ,23,Not available,Not available,"Phyllomedusa hypochondrialis",Native peptide,"Horse erythrocytes: 1% Hemolysis=16µM; 3% Hemolysis=64µM; 10% Hemolysis=128µM; 45% Hemolysis=256µM; 100% Hemolysis=512µM","HMEC-1: IC50=4.85µM","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep00800,Not available,DCTPep00800.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2536.96,2535.42,8.54,CDFHMPRSTY,ALN,C114H190N32O33,1,2,3,5,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.168","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",20.85,127.39,-0.096,"29064402++Dermaseptin-PH: A Novel Peptide with Antimicrobial and Anticancer Activities from the Skin Secretion of the South American Orange-Legged Leaf Frog, Pithecopus (Phyllomedusa) hypochondrialis++10.3390/molecules22101805++2017",Not available,Not available,"Not available",Not available,positive
DCTPep00830,Not available,Not available,Not available,Not available,"K5, 17-DPS3",ALWKKILKNAGKAALNKINQIVQ,23,Not available,Not available,"skin secretion of Phyllomedusa sauvagii",Native peptide,"Horse blood cells: HC50=14.98 μM","HMEC-1: IC50=123.00 μM","Not available",Not available,"Not available",Anticancer; Antitumor; Antimicrobial,Not available,DCTPep00830,Not available,DCTPep00830.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2563.13,2561.55,10.60,CDEFHMPRSTY,K,C118H204N34O29,5,0,5,4,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.146","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",16.8,131.74,-0.087,"30087268++Biological Activities of Cationicity-Enhanced and Hydrophobicity-Optimized Analogues of an Antimicrobial Peptide, Dermaseptin-PS3, from the Skin Secretion of Phyllomedusa sauvagii++10.3390/toxins10080320++2018",Not available,Not available,"Not available",Not available,positive
DCTPep01095,Not available,Not available,Not available,Not available,"DRS B3",ALWKNMLKGIGKLAGQAALGAVKTLVGA,28,P81485##P83641##C0HLD2,Not available,"Dermaseptins B",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antimicrobial,Not available,DCTPep01095,Not available,DCTPep01095.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2780.41,2778.63,10.48,CDEFHPRSY,A,C127H219N35O32S1,4,0,4,7,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.978","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-7.19,125.71,0.657,"9614066++Structure, synthesis, and molecular cloning of dermaseptins B, a family of skin peptide antibiotics++10.1074/jbc.273.24.14690++1998",Not available,Not available,"Not available",Not available,positive
DCTPep03710,Not available,Not available,11805,Not available,"Dermaseptin DRS-DU-1",ALWKSLLKNVGKAAGKAALNAVTDMVNQ,28,A0A345FZ90,Not available,"Animalia",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2912.44,2910.61,10.00,CEFHIPRY,A,C129H219N37O37S1,3,1,4,7,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.888","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",0.25,108.21,0.150,"30258724++Discovery of two skin-derived dermaseptins and design of a TAT-fusion analogue with broad-spectrum antimicrobial activity and low cytotoxicity on healthy cells++10.7717/peerj.5635++2018",Not available,Not available,"Not available",Not available,positive
DCTPep00487,Not available,Not available,Not available,Not available,"Dermaseptin S4 [M4K][N20K]",ALWKTLLKKVLKAAAKAALKAVLVGANA,28,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 50% Hemolysis=0.5±0.2 µM","Vero cells: 50% Cytotoxicity =25 µM","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal; Antiviral,Not available,DCTPep00487,Not available,DCTPep00487.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2861.6,2859.82,10.70,CDEFHIMPQRSY,A,C135H238N36O31,6,0,6,3,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.922","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-0.09,146.79,0.811,"24492362++In vitro activities of dermaseptins K4S4 and K4K20S4 against Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa planktonic growth and biofilm formation++10.1128/AAC.02142-13++2014##10660589++Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity++10.1074/jbc.275.6.4230++2000##11847217++Structural requirements for potent versus selective cytotoxicity for antimicrobial dermaseptin S4 derivatives++10.1074/jbc.M111071200++2002",Not available,Not available,"Not available",Not available,positive
DCTPep00488,Not available,Not available,Not available,Not available,"Dermaseptin S4 [M4K]",ALWKTLLKKVLKAAAKAALNAVLVGANA,28,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 50% Hemolysis=2±0.1 µM","BHK-21 BSR: 10.5% Cytotoxicity =10 µM; Vero cells: 50% Cytotoxicity =12 µM","Not available",Not available,"Not available",Anticancer; Antibacterial; Antiviral,Not available,DCTPep00488,Not available,DCTPep00488.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2847.53,2845.76,10.60,CDEFHIMPQRSY,A,C133H232N36O32,5,0,5,4,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.931","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",2.94,146.79,0.825,"24492362++In vitro activities of dermaseptins K4S4 and K4K20S4 against Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa planktonic growth and biofilm formation++10.1128/AAC.02142-13++2014##10660589++Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity++10.1074/jbc.275.6.4230++2000##23161023++In vitro antiviral activity of dermaseptin S(4) and derivatives from amphibian skin against herpes simplex virus type 2++10.1002/jmv.23450++2013##29439871++Dermaseptins as potential antirabies compounds++10.1016/j.vaccine.2018.01.066++2019",Not available,Not available,"Not available",Not available,positive
DCTPep03738,Not available,Not available,12112,Not available,"Dermaseptin-PS1, Dermaseptin cDNA",ALWKTMLKKLGTVALHAGKAALGAVADTISQ,31,A0A284T6N8,Not available,"Animalia",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,3164.8,3162.8,10.00,CEFNPRY,A,C143H243N39O39S1,4,1,5,7,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.738","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",2.25,116.77,0.503,"30461197++Novel peptide dermaseptin-PS1 exhibits anticancer activity via induction of intrinsic apoptosis signalling++Not available++2018",Not available,Not available,"Not available",Not available,positive
DCTPep00122,Not available,Not available,Not available,Not available,"Agrocybin",ANDPQCLYGNVAAKF,15,Not available,Not available,"Agrocybe cylindracea",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep00122,Not available,DCTPep00122.cif,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,1610.8,1609.76,5.87,EHIMRSTW,A,C71H107N19O22S1,0,1,1,5,"Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.925, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.925, assuming all Cys residues are reduced","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",18.67,65.33,-0.167,"15629530++Agrocybin, an antifungal peptide from the edible mushroom Agrocybe cylindracea++10.1016/j.peptides.2004.09.011++2005",Not available,Not available,"Not available",Not available,positive
DCTPep04820,Not available,Not available,Not available,Not available,"Anginex",ANIKLSVQMKLFKRHLKWKIIVKLNDGRELSLDA,34,Not available,Not available,"PF4",Synthetic peptide,"Not available","Not available","Galectin 1",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer targeted peptides,Not available,Linear,"Not available","Free",Free,None,L,4006.86,4004.32,10.29,CPTY,KL,C183H310N52O46S1,6,3,9,5,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.373","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",15.14,126.18,-0.191,"21470139++Anti-angiogenic peptides for cancer therapeutics++10.2174/138920111796117300++2011",Not available,Not available,"Not available",Not available,positive
DCTPep04821,Not available,Not available,Not available,Not available,"Fibrinogen derived",ARPAKAAATQKKVERKAPDA,20,Not available,Not available,"Fibrinogen",Synthetic peptide,"Not available","Not available","αvβ3",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer targeted peptides,Not available,Linear,"Not available","Free",Free,None,L,2107.44,2106.2,10.45,CFGHILMNSWY,A,C90H159N31O27,4,2,6,1,"Should not be visible by UV spectrophotometry.","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",26.61,49.50,-1.110,"21470139++Anti-angiogenic peptides for cancer therapeutics++10.2174/138920111796117300++2011",Not available,Not available,"Not available",Not available,positive
DCTPep01143,Not available,Not available,Not available,Not available,"SEQ ID NO 6 from EP1783140A3",ASSSYPLIHWRPWAR,15,Not available,Not available,"Screen of phage display peptide library",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep01143,Not available,DCTPep01143.cif,ACP,Not available,Linear,"Not available","Free",Free,None,L,1827.08,1825.94,10.84,CDEFGKMNQTV,S,C86H123N25O20,3,0,3,4,"Ext. coefficient    12490##Abs 0.1% (=1 g/l)   6.836","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",50.45,65.33,-0.600,"Not available++Not available++Not available++Not available",EP1783140A3,Neovascular-specific peptides,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",EP1783140A3##AT453667T##CA2347136A1##CA2622786A1##CY1109881T1##DK1122262T3##EP1122262A1##EP1122262A4##EP1122262B1##ES2337321T3##JP4439120B2##PT1122262E##US6753310B1##WO0023476A1,positive
DCTPep00670,Not available,Not available,Not available,Not available,"Bacteriocin TP",ASVVNKLTGGVAGLLK,16,Not available,Not available,"Bacillus subtilis",Native peptide,"Mouse erythrocytes: <10% Hemolysis=160µM; 10% Hemolysis=320µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00670,Not available,DCTPep00670.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,1526.84,1525.92,10.00,CDEFHIMPQRWY,GLV,C68H123N19O20,2,0,2,6,"Should not be visible by UV spectrophotometry.","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",15.97,140.00,0.850,"28254375++Isolation and characterisation of a novel antibacterial peptide from a native swine intestinal tract-derived bacterium++10.1016/j.ijantimicag.2016.12.012++2017",Not available,Not available,"Not available",Not available,positive
DCTPep04822,Not available,Not available,Not available,Not available,"Fibulostatin-6.2",ASWSACSVSCGGGARQRTR,19,Not available,Not available,"Homo sapiens (Fibulin-6)",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Not available,"Not available","Free",Free,None,L,1940.14,1938.89,10.41,DEFHIKLMNPY,S,C76H126N30O26S2,3,0,3,10,"Ext. coefficient     5625##Abs 0.1% (=1 g/l)   2.899, assuming all pairs of Cys residues form cystines##Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.835, assuming all Cys residues are reduced","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",68.42,31.05,-0.442,"18780781++A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells++10.1073/pnas.0803241105++2008",Not available,Not available,"Not available",Not available,positive
DCTPep04697,DRAMP00232,Not available,Not available,Not available,"Cypemycin (Bacteriocin)",ATPATPTVAQFVIQGSTICLVC,22,E5KIB6,Not available,"Streptomyces",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Not available,"Not available","Free",Free,None,L,2220.63,2219.13,5.55,DEHKMNRWY,T,C98H162N24O30S2,0,0,0,8,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.056, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",23.63,106.36,1.109,"7802859++Not available++Not available++Not available##20805503++Not available++Not available++Not available",Not available,Not available,"Not available",Not available,positive
DCTPep04823,Not available,Not available,Not available,Not available,"Hexastatin-1",ATPFIECSGARGTCHYFAN,19,Not available,Not available,"Homo sapiens (α6 CIV)",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Not available,"Not available","Free",Free,None,L,2045.27,2043.89,6.77,DKLMQVW,A,C89H129N25O27S2,1,1,2,9,"Ext. coefficient     1615##Abs 0.1% (=1 g/l)   0.790, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.729, assuming all Cys residues are reduced","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",92.74,36.32,-0.005,"18780781++A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells++10.1073/pnas.0803241105++2008",Not available,Not available,"Not available",Not available,positive
DCTPep00326,Not available,Not available,Not available,Not available,"Z8",AWKKWAKAWKWAKAKWWAKAA,21,Not available,Not available,"Synthetic",Synthetic peptide,"MRC-5: EC57=17 μM","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00326,Not available,DCTPep00326.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2601.14,2599.45,10.78,CDEFGHILMNPQRSTVY,A,C132H186N34O22,7,0,7,0,"Ext. coefficient    33000##Abs 0.1% (=1 g/l)  12.687","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-11.95,38.10,-0.871,"22057278++Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity++10.1074/jbc.M111.279281++2012",Not available,Not available,"Not available",Not available,positive
DCTPep02767,Not available,Not available,DBAASPS_16627,Not available,"Gradient2",AWLKRIKKFLKALFWVWVW,19,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep02767,Not available,DCTPep02767.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,2519.17,2517.49,11.33,CDEGHMNPQSTY,KW,C132H192N30O20,5,0,5,0,"Ext. coefficient    22000##Abs 0.1% (=1 g/l)   8.733","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",10.78,123.16,0.516,"31375699++In silico design and optimization of selective membranolytic anticancer peptides++10.1038/s41598-019-47568-9++2019",Not available,Not available,"Not available",Not available,positive
DCTPep00925,Not available,Not available,Not available,Not available,"EeCentrocin 1 Chain A (1-12)[G1A, D8A, N12K]",AWWRRTVAKVRK,12,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes:0% Hemolysis=25 µM; 1.6% Hemolysis=200 µM","MRC-5: IC50>100 µM","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,1556.88,1555.92,12.31,CDEFGHILMNPQSY,R,C72H117N25O14,5,0,5,1,"Ext. coefficient    11000##Abs 0.1% (=1 g/l)   7.065","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",49.82,65.00,-0.983,"31802582++Structure-activity relationship studies of shortened analogues of the antimicrobial peptide EeCentrocin 1 from the sea urchin Echinus esculentus++10.1002/psc.3233++2019",Not available,Not available,"Not available",Not available,positive
DCTPep04824,Not available,Not available,Not available,Not available,"aa 176-194",AWYRGAAPPKQEFLDIEDP,19,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Not available,"Not available","Free",Free,None,L,2203.44,2202.07,4.32,CHMNSTV,AP,C102H147N25O30,-2,4,2,2,"Ext. coefficient     6990##Abs 0.1% (=1 g/l)   3.172","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",67.77,56.84,-0.884,"Not available++Not available++Not available++Not available",US20020086420A1,Not available,"Not available",Not available,positive
DCTPep02041,Not available,3143##3144##3145,Not available,Not available,"PTPRJ pep-19.2",CAHNLTHAC,9,Not available,Not available,"Synthetic (Derived from PTPRJ pep-19)",Synthetic peptide,"Not available","Not available","PTPRJ",Not available,"PTPRJ is a receptor-type protein tyrosine phosphatase whose expression is strongly reduced in the majority of investigated cancer cell lines and tumor specimens.It showed tumor suppressor activity in several models.",Anticancer,Not available,Not available,Not available,Not available,ACP##Tumor active peptide##Cancer targeted peptides##PTPRJ agonist,Not available,Cyclic,"Cys1<--->Cys9","Free",Free,None,L,969.1,968.4,6.90,DEFGIKMPQRSVWY,ACH,C38H60N14O12S2,2,0,2,4,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.129, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",74.59,65.56,0.200,"23627474++Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation++10.1021/cb3007192++2013",Not available,Not available,"Not available",Not available,positive
DCTPep00116,Not available,Not available,Not available,Not available,"V5",CAKAKAKAGSGAKAKAKAC,19,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 50% Hemolysis=1055 µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00116,Not available,DCTPep00116.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Cyclic,"Cys1<--->Cys19","Acetylization",Amidation,None,L,1763.15,1761.97,10.05,DEFHILMNPQRTVWY,A,C73H135N25O21S2,6,0,6,5,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.071, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",28.13,42.11,-0.295,"15328096++De novo design of potent antimicrobial peptides++10.1128/AAC.48.9.3349-3357.2004++2004",Not available,Not available,"Not available",Not available,positive
DCTPep04825,Not available,Not available,Not available,Not available,"E-selectin-binding peptide",CDSDSDITWDQLWDLMK,17,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,2071.26,2069.87,3.66,AEFGHNPRVY,D,C89H131N21O32S2,-4,5,1,4,"Ext. coefficient    11000##Abs 0.1% (=1 g/l)   5.311, assuming all pairs of Cys residues form cystines##Ext. coefficient    11000##Abs 0.1% (=1 g/l)   5.311, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",48.49,68.82,-0.735,"17121909++How molecular imaging is speeding up antiangiogenic drug development++10.1158/1535-7163.MCT-06-0395++2006",Not available,Not available,"Not available",Not available,positive
DCTPep04827,Not available,Not available,Not available,Not available,"FSEC",CELDENNTPMC,11,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,1268.39,1267.45,3.57,AFGHIKQRSVWY,CEN,C48H77N13O21S3,-3,3,0,5,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.099, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-5.48,35.45,-0.827,"11311231++A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor++10.1016/s0014-5793(01)02314-6++2001",Not available,Not available,"Not available",Not available,positive
DCTPep04744,Not available,Not available,Not available,Not available,"PaDef",CETPSKHFNGLCIRSSNCASVCHGEHFTDGRCQGVRRRCMCLKPC,45,Not available,Not available,"Persea americana",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Not available,"Not available","Free",Free,None,L,5028.82,5025.23,8.77,WY,C,C203H329N71O61S9,7,3,10,20,"Ext. coefficient      500##Abs 0.1% (=1 g/l)   0.099, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",51.17,41.11,-0.456,"24319695++Not available++Not available++Not available",Not available,Not available,"Not available",Not available,positive
DCTPep04828,Not available,Not available,Not available,Not available,"Endostatin fragment IV, IVox",CETWRTETTGATGQASSLLSGRLLEQKAASCHNSYIVLCIENSFMTSFSK,50,Not available,Not available,"Collagen XVIII",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Not available,"Not available","Free",Free,None,L,5459.14,5455.59,6.74,DP,S,C233H371N65O78S4,1,4,5,23,"Ext. coefficient     7115##Abs 0.1% (=1 g/l)   1.303, assuming all pairs of Cys residues form cystines##Ext. coefficient     6990##Abs 0.1% (=1 g/l)   1.280, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",37.55,68.40,-0.152,"21470139++Anti-angiogenic peptides for cancer therapeutics++10.2174/138920111796117300++2011",Not available,Not available,"Not available",Not available,positive
DCTPep00117,Not available,Not available,Not available,Not available,"V6",CFKFKFKFGSGFKFKFKFC,19,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 50% Hemolysis=35 µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00117,Not available,DCTPep00117.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Cyclic,"Cys1<--->Cys19","Acetylization",Amidation,None,L,2371.93,2370.22,10.05,ADEHILMNPQRTVWY,F,C121H167N25O21S2,6,0,6,5,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.053, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-37.99,0.00,0.126,"15328096++De novo design of potent antimicrobial peptides++10.1128/AAC.48.9.3349-3357.2004++2004",Not available,Not available,"Not available",Not available,positive
DCTPep03902,Not available,Not available,14104,Not available,"HLopt2",CFQWKRAMRKVR,12,P02788,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,1608.99,1607.87,11.72,DEGHILNPSTY,R,C71H117N25O14S2,5,0,5,1,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.418, assuming all pairs of Cys residues form cystines##Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.418, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",22.97,32.50,-1.042,"31513374++Antibiotic-Based Conjugates Containing Antimicrobial HLopt2 Peptide: Design, Synthesis, Antimicrobial and Cytotoxic Activities++10.1021/acschembio.9b00538++2019",Not available,Not available,"Not available",Not available,positive
DCTPep04757,Not available,Not available,Not available,Not available,"Cycloviolacin O2",CGESCVWIPCISSAIGCSCKSKVCYRNGIP,30,Not available,Not available,"Viola odorata",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Cyclic,"Cys1<--->Cys18; Cys5<--->Cys20; Cys10<--->Cys25","Free",Free,None,L,3164.75,3162.43,8.33,DFHLMQT,C,C133H215N37O40S6,2,1,3,16,"Ext. coefficient     7365##Abs 0.1% (=1 g/l)   2.327, assuming all pairs of Cys residues form cystines##Ext. coefficient     6990##Abs 0.1% (=1 g/l)   2.209, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",22.59,74.67,0.443,"10600388++Plant cyclotides: A unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif++10.1006/jmbi.1999.3383++1999",Not available,Not available,"Not available",Not available,positive
DCTPep02042,Not available,3146##3147##3148,Not available,Not available,"PTPRJ pep-19.3",CHANLTHAC,9,Not available,Not available,"Synthetic (Derived from PTPRJ pep-19)",Synthetic peptide,"Not available","Not available","PTPRJ",Not available,"PTPRJ is a receptor-type protein tyrosine phosphatase whose expression is strongly reduced in the majority of investigated cancer cell lines and tumor specimens.It showed tumor suppressor activity in several models.",Anticancer,Not available,Not available,Not available,Not available,ACP##Tumor active peptide##Cancer targeted peptides##PTPRJ agonist,Not available,Cyclic,"Cys1<--->Cys9","Free",Free,None,L,969.1,968.4,6.90,DEFGIKMPQRSVWY,ACH,C38H60N14O12S2,2,0,2,4,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.129, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",93.93,65.56,0.200,"23627474++Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation++10.1021/cb3007192++2013",Not available,Not available,"Not available",Not available,positive
DCTPep02039,Not available,3140##3141##3142,Not available,Not available,"PTPRJ pep-19",CHHNLTHAC,9,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","PTPRJ",Not available,"PTPRJ is a receptor-type protein tyrosine phosphatase whose expression is strongly reduced in the majority of investigated cancer cell lines and tumor specimens.It showed tumor suppressor activity in several models.",Anticancer,Not available,Not available,Not available,Not available,Cancer targeted peptides##PTPRJ agonist,Not available,Cyclic,"Cys1<--->Cys9","Free",Free,None,L,1035.16,1034.42,7.00,DEFGIKMPQRSVWY,H,C41H62N16O12S2,3,0,3,4,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.121, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",120.24,54.44,-0.356,"23627474++Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation++10.1021/cb3007192++2013",Not available,Not available,"Not available",Not available,positive
DCTPep02040,Not available,Not available,Not available,Not available,"PTPRJ pep-19.0",CHHNLTHAC,9,Not available,Not available,"Synthetic (Derived from PTPRJ pep-19)",Synthetic peptide,"Not available","Not available","PTPRJ",Not available,"PTPRJ is a receptor-type protein tyrosine phosphatase whose expression is strongly reduced in the majority of investigated cancer cell lines and tumor specimens.It showed tumor suppressor activity in several models.",Anticancer,Not available,Not available,Not available,Not available,Cancer targeted peptides##PTPRJ agonist,Not available,Linear,"Not available","Free",Free,None,L,1035.16,1034.42,7.00,DEFGIKMPQRSVWY,H,C41H62N16O12S2,3,0,3,4,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.121, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",120.24,54.44,-0.356,"23627474++Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation++10.1021/cb3007192++2013",Not available,Not available,"Not available",Not available,positive
DCTPep02491,Not available,Not available,Not available,Not available,"P6V8-3NCS1-7CC (SEQ ID NO:12 for Patent US 20030186868 A1)",CKGRGKRCREKQRPSDKPRR,20,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","VEGF165",Not available,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-5, without affecting VEGF signaling through other pathways.",Anticancer,Not available,DCTPep02491,Not available,DCTPep02491.cif,ACP##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,Not available,Cyclic,"Cys1<--->Cys8","Free",Free,None,L,2441.86,2440.32,11.38,AFHILMNTVWY,R,C97H177N43O27S2,8,2,10,5,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.051, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",61.02,0.00,-2.645,"Not available++Not available++Not available++Not available",US 20030186868 A1,Anti-angiogenic peptides,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",AU2002340080A1##US7052705B2##WO03029275A2##WO03029275A3,positive
DCTPep03704,Not available,Not available,11531,Not available,"PTN (42-61)",CKILSKTIKCRIPCGRRKEY,20,C3Z937,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,2395.97,2394.32,9.93,ADFHMNQVW,K,C103H183N33O26S3,6,1,7,7,"Ext. coefficient     1615##Abs 0.1% (=1 g/l)   0.674, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.622, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",34.07,78.00,-0.630,"30096337++Identification and Characterization of Novel Antimicrobial Peptide from Hippocampus comes by In Silico and Experimental Studies++Not available++2018",Not available,Not available,"Not available",Not available,positive
DCTPep04837,Not available,Not available,Not available,Not available,"AA 128-175; loop-4+loop-5+loop-6",CKITRCPMIPCYISSPDECLWMDWVTEKNINGHQAKFFACIKRSDGSC,48,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Cyclic,"Not available","Free",Free,None,L,5527.46,5523.53,7.77,Not Applicable,C,C240H371N65O69S8,2,5,7,17,"Ext. coefficient    12865##Abs 0.1% (=1 g/l)   2.327, assuming all pairs of Cys residues form cystines##Ext. coefficient    12490##Abs 0.1% (=1 g/l)   2.260, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",79.54,58.96,-0.221,"Not available++Not available++Not available++Not available",US20020086420A1,Not available,"Not available",Not available,positive
DCTPep03773,Not available,Not available,12435,Not available,"Brachyin",CLGENVPCDKDRPNCCSRYECLEPTGYGWWYASYYCYKKRS,41,Not available,Not available,"Animalia",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Insect,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,4908.52,4905.1,7.74,FHIMQ,CY,C215H309N57O64S6,1,5,6,21,"Ext. coefficient    20315##Abs 0.1% (=1 g/l)   4.139, assuming all pairs of Cys residues form cystines##Ext. coefficient    19940##Abs 0.1% (=1 g/l)   4.062, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",65.64,28.54,-0.971,"25329070++A novel neurotoxin from venom of the spider, Brachypelma albopilosum++Not available++2014",Not available,Not available,"Not available",Not available,positive
DCTPep00815,Not available,Not available,Not available,Not available,"cMP-C",CLNLKALLAVAKKILC,16,Not available,Not available,"wasp venom",Native peptide,"Horse erythrocytes: HC50=40.11 μM","HMEC-1: IC50=57.15 μM","Not available",Not available,"Not available",Anticancer; Antitumor; Antimicrobial,Not available,DCTPep00815,Not available,DCTPep00815.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,1714.24,1713.04,9.39,DEFGHMPQRSTWY,L,C78H144N20O18S2,3,0,3,3,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.073, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",22.84,183.12,1.431,"29904274++Evaluation of the bioactivity of a mastoparan peptide from wasp venom and of its analogues designed through targeted engineering++10.7150/ijbs.23419++2018",Not available,Not available,"Not available",Not available,positive
DCTPep03597,Not available,Not available,8125,Not available,"CK21",CNGRCGGKLAKLAKKLAKLAK,21,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Cyclic,"Cyc1<--->Cyc5","Free",Free,None,L,2171.74,2170.29,10.32,DEFHIMPQSTVWY,K,C94H175N31O23S2,7,0,7,6,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.058, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-11.97,93.33,-0.248,"25990455++An antimicrobial peptide containing NGR motif has potent antitumor activity against CD13+ and CD13- tumor cells++Not available++2015",Not available,Not available,"Not available",Not available,positive
DCTPep04839,Not available,Not available,Not available,Not available,"FSEN",CQNHHAKHGKVC,12,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,1361.56,1360.62,8.91,DEFILMPRSTWY,H,C55H88N22O15S2,5,0,5,4,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.092, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-19.91,32.50,-1.150,"11311231++A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor++10.1016/s0014-5793(01)02314-6++2001",Not available,Not available,"Not available",Not available,positive
DCTPep00482,Not available,Not available,DBAASPS_10332,Not available,"BP327",CREKAKKLFKKILKKL,16,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","NIH 3T3: IC50=74.5±4.1µM","Not available",Not available,"Not available",Anticancer,Not available,DCTPep00482,Not available,DCTPep00482.cif,ACP##Tumor active peptide##Coupling peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1974.57,1973.27,10.40,DGHMNPQSTVWY,K,C92H168N26O19S1,7,1,8,1,"Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-9.21,103.75,-0.769,"24480922++Identification of BP16 as a non-toxic cell-penetrating peptide with highly efficient drug delivery properties++10.1039/c3ob42422g++2014",Not available,Not available,"Not available",Not available,positive
DCTPep00948,Not available,Not available,Not available,Not available,"BP329",CREKAKKLFKKILKKL,16,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","NIH 3T3: IC50=33.7 ± 1.9 µM","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,Not available,Not available,Not available,ACP##Tumor active peptide##Coupling peptide,Not available,Linear,"Not available","Chlorambucil",Amidation,None,L,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Not Applicable","Not Applicable",Not Applicable,Not Applicable,Not Applicable,"24480922++Identification of BP16 as a non-toxic cell-penetrating peptide with highly efficient drug delivery properties++10.1039/c3ob42422g++2014",Not available,Not available,"Not available",Not available,positive
DCTPep00244,Not available,Not available,Not available,Not available,"Peptide-20",CSSRTMHHC,9,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","cadherin constituent at the tumor cell surface",Not available,"Not available",Anticancer; Antitumor,Not available,Not available,Not available,Not available,ACP##Tumor active peptide##Cancer targeted peptides,Not available,Cyclic,"Not available","Free",Free,None,L,1061.22,1060.4,8.09,ADEFGIKLNPQVWY,CHS,C39H64N16O13S3,3,0,3,5,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.118, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",115.33,0.00,-0.700,"20802991++A novel melanoma-targeting peptide screened by phage display exhibits antitumor activity++10.1007/s00109-010-0671-9++2010",Not available,Not available,"Not available",Not available,positive
DCTPep00112,Not available,Not available,Not available,Not available,"V1",CVKVKVKVGSGVKVKVKVC,19,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 50% Hemolysis=880 µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00112,Not available,DCTPep00112.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Cyclic,"Cys1<--->Cys19","Acetylization",Amidation,None,L,1987.58,1986.22,10.05,ADEFHILMNPQRTWY,V,C89H167N25O21S2,6,0,6,5,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.063, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-34.87,122.11,0.716,"15328096++De novo design of potent antimicrobial peptides++10.1128/AAC.48.9.3349-3357.2004++2004",Not available,Not available,"Not available",Not available,positive
DCTPep00115,Not available,Not available,Not available,Not available,"V4",CVKVQVKVGSGVKVQVKVC,19,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 50% Hemolysis=3226 µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00115,Not available,DCTPep00115.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Cyclic,"Cys1<--->Cys19","Acetylization",Amidation,None,L,1987.49,1986.15,9.70,ADEFHILMNPRTWY,V,C87H159N25O23S2,4,0,4,5,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.063, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-30.84,122.11,0.758,"15328096++De novo design of potent antimicrobial peptides++10.1128/AAC.48.9.3349-3357.2004++2004",Not available,Not available,"Not available",Not available,positive
DCTPep00114,Not available,Not available,Not available,Not available,"V3",CVKVRVKVGSGVKVRVKVC,19,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 50% Hemolysis=590 µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00114,Not available,DCTPep00114.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Cyclic,"Cys1<--->Cys19","Acetylization",Amidation,None,L,2043.61,2042.23,10.48,ADEFHILMNPQTWY,V,C89H167N29O21S2,6,0,6,5,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.061, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-22.9,122.11,0.653,"15328096++De novo design of potent antimicrobial peptides++10.1128/AAC.48.9.3349-3357.2004++2004",Not available,Not available,"Not available",Not available,positive
DCTPep00113,Not available,Not available,Not available,Not available,"V2",CVKVSVKVGSGVKVSVKVC,19,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 50% Hemolysis=589 µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00113,Not available,DCTPep00113.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Cyclic,"Cys1<--->Cys19","Acetylization",Amidation,None,L,1905.39,1904.1,9.70,ADEFHILMNPQRTWY,V,C83H153N23O23S2,4,0,4,7,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.066, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-22.9,122.11,1.042,"15328096++De novo design of potent antimicrobial peptides++10.1128/AAC.48.9.3349-3357.2004++2004",Not available,Not available,"Not available",Not available,positive
DCTPep03586,Not available,Not available,7862,Not available,"Ep-AMP1",CVLIGQRCDNDRGPRCCSGQGNCVPLPFLGGVCAV,35,Not available,Not available,"Plantae",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep03586,2MFS,DCTPep03586.cif,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,3608.22,3605.66,7.78,EHKMTWY,CG,C148H244N48O45S6,1,2,3,15,"Ext. coefficient      375##Abs 0.1% (=1 g/l)   0.104, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",20.96,80.57,0.280,"25821084++A Cactus-Derived Toxin-Like Cystine Knot Peptide with Selective Antimicrobial Activity++Not available++2015",Not available,Not available,"Not available",Not available,positive
DCTPep00118,Not available,Not available,Not available,Not available,"V7",CWKWKWKWGSGWKWKWKWC,19,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 50% Hemolysis=45 µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00118,Not available,DCTPep00118.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Cyclic,"Cys1<--->Cys19","Acetylization",Amidation,None,L,2684.23,2682.31,10.05,ADEFHILMNPQRTVY,W,C137H175N33O21S2,6,0,6,5,"Ext. coefficient    44125##Abs 0.1% (=1 g/l)  16.439, assuming all pairs of Cys residues form cystines##Ext. coefficient    44000##Abs 0.1% (=1 g/l)  16.392, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",22.97,0.00,-1.432,"15328096++De novo design of potent antimicrobial peptides++10.1128/AAC.48.9.3349-3357.2004++2004",Not available,Not available,"Not available",Not available,positive
DCTPep04003,Not available,Not available,15442,Not available,"GBV-A10 [P16L]",CWVRLGRYLLRRLKTLFT,18,O41892,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antiviral,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,2294.84,2293.34,11.56,ADEHIMNPQS,L,C107H176N32O22S1,5,0,5,5,"Ext. coefficient     6990##Abs 0.1% (=1 g/l)   3.046, assuming all pairs of Cys residues form cystines##Ext. coefficient     6990##Abs 0.1% (=1 g/l)   3.046, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",51.5,124.44,0.144,"23175359++Screening and Rational Design of Hepatitis C Virus Entry Inhibitory Peptides Derived From GB Virus A NS5A++Not available++2013",Not available,Not available,"Not available",Not available,positive
DCTPep01308,Not available,Not available,Not available,Not available,"Sequence 5 from Patent US 20100279918",DAATATRGRSAASRPTERPRAPARSASRPRRVD,33,Not available,Not available,"Herpes simplex virus type",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,DCTPep01308,Not available,DCTPep01308.cif,ACP,Not available,Not available,"Not available","Not available",Not available,None,L,3547.91,3545.89,12.10,CFHIKLMNQWY,R,C142H248N60O47,6,3,9,8,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",88.68,33.03,-1.348,"Not available++Not available++Not available++Not available",US 2010/0279918 A1,Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.,"Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status:   Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;",DE602007011901D1##EP1991586A1##EP1991586B1##WO2007108749A1##WO2007108749A8,positive
DCTPep04842,Not available,Not available,Not available,Not available,"TSP-1",DDDDDNDKIPDDRDN,15,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,1776.66,1775.67,3.62,ACEFGHLMQSTVWY,D,C67H101N21O36,-7,9,2,2,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-13.96,26.00,-2.933,"20056600++Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds++10.1074/jbc.M109.085605++2010",Not available,Not available,"Not available",Not available,positive
DCTPep03619,Not available,Not available,8767,Not available,"XLAsp-P1",DEDDD,5,Not available,Not available,"Xenopus laevis",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Not Applicable","Not Applicable",Not Applicable,Not Applicable,Not Applicable,"26952034++A novel short anionic antibacterial peptide isolated from the skin of Xenopus laevis with broad antibacterial activity and inhibitory activity against breast cancer cell++Not available++2016",Not available,Not available,"Not available",Not available,positive
DCTPep04844,Not available,Not available,Not available,Not available,"C16S",DFKLFAVTIKYR,12,Not available,Not available,"Laminin",Synthetic peptide,"Not available","Not available","αvβ3, α5β1",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer targeted peptides,Not available,Linear,"Not available","Free",Free,None,L,1500.8,1499.85,9.70,CEGHMNPQSW,FK,C73H113N17O17,2,1,3,2,"Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.993","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-44.96,97.50,0.175,"21470139++Anti-angiogenic peptides for cancer therapeutics++10.2174/138920111796117300++2011",Not available,Not available,"Not available",Not available,positive
DCTPep04845,Not available,Not available,Not available,Not available,"C16Y",DFKLFAVYIKYR,12,Not available,Not available,"Laminin",Synthetic peptide,"Not available","Not available","αvβ3, α5β1",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer targeted peptides,Not available,Linear,"Not available","Free",Free,None,L,1562.87,1561.87,9.53,CEGHMNPQSTW,FKY,C78H115N17O17,2,1,3,2,"Ext. coefficient     2980##Abs 0.1% (=1 g/l)   1.907","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-44.17,97.50,0.125,"21470139++Anti-angiogenic peptides for cancer therapeutics++10.2174/138920111796117300++2011",Not available,Not available,"Not available",Not available,positive
DCTPep02514,Not available,Not available,Not available,Not available,"Chemokinostatin-8",DGRELCLDPKENWVQRVVEKFLK,23,P10145,Not available,"Homo sapiens (CXCL8/IL-8)",Native peptide,"Not available","Not available","CXCR",Not available,"Not available",Anticancer,Not available,DCTPep02514,Not available,DCTPep02514.cif,Cancer targeted peptides##Antiangiogenic,Not available,Linear,"Not available","Free",Free,None,L,2802.24,2800.47,6.27,AHIMSTY,EKLV,C125H201N35O36S1,0,5,5,3,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.963, assuming all pairs of Cys residues form cystines##Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.963, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",6.05,88.70,-0.817,"18307172++Novel anti-angiogenic peptides derived from ELR-containing CXC chemokines++10.1002/jcb.21712++2008",Not available,Not available,"Not available",Not available,positive
DCTPep02513,Not available,Not available,Not available,Not available,"Chemokinostatin-7",DGRKICLDPDAPRIKKIVQKKL,22,P02775,Not available,"Homo sapiens (CXCL7/PBP)",Native peptide,"Not available","Not available","CXCR",Not available,"Not available",Anticancer,Not available,DCTPep02513,Not available,DCTPep02513.cif,Cancer targeted peptides##Antiangiogenic,Not available,Linear,"Not available","Free",Free,None,L,2535.09,2533.49,9.86,EFHMNSTWY,K,C112H200N34O30S1,4,3,7,2,"Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",0.9,106.36,-0.750,"18307172++Novel anti-angiogenic peptides derived from ELR-containing CXC chemokines++10.1002/jcb.21712++2008",Not available,Not available,"Not available",Not available,positive
DCTPep03541,Not available,Not available,7009,Not available,"Sus scrofa Uncharacterized protein (208-235), SP-E",DKPKKKPPPPAGPPPPPPPPPGPPPPGP,28,F1SQ50,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep03541,Not available,DCTPep03541.cif,Cell-penetrating peptides,Not available,Linear,"Not available","Free",Free,None,L,2733.25,2731.52,10.00,CEFHILMNQRSTVWY,P,C132H202N32O31,3,1,4,3,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",104.4,3.57,-1.746,"30046246++The activity of a mammalian proline-rich peptide against Gram-negative bacteria, including drug-resistant strains, relies on a nonmembranolytic mode of action++Not available++2018##23274276++Structural and functional studies on a proline-rich peptide isolated from swine saliva endowed with antifungal activity towards Cryptococcus neoformans++Not available++2013",Not available,Not available,"Not available",Not available,positive
DCTPep04849,Not available,Not available,Not available,Not available,"PEDF P18",DPFFKVPVNKLAAAVSNFGYDLYRVRSSTSPTTN,34,Not available,Not available,"PEDF",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,3763.22,3760.92,9.52,CEHIMQW,SV,C171H261N45O51,2,2,4,13,"Ext. coefficient     2980##Abs 0.1% (=1 g/l)   0.792","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",46.41,65.88,-0.271,"21470139++Anti-angiogenic peptides for cancer therapeutics++10.2174/138920111796117300++2011",Not available,Not available,"Not available",Not available,positive
DCTPep04850,Not available,Not available,Not available,Not available,"PEDF 34-mer fragment",DPFFKVPVNKLAAVSNFGYDLYRVRSSMSPTTN,33,Not available,Not available,"PEDF",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,3722.23,3719.88,9.52,CEHIQW,SV,C169H258N44O49S1,2,2,4,12,"Ext. coefficient     2980##Abs 0.1% (=1 g/l)   0.801","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",60.83,64.85,-0.255,"21470139++Anti-angiogenic peptides for cancer therapeutics++10.2174/138920111796117300++2011",Not available,Not available,"Not available",Not available,positive
DCTPep02326,Not available,Not available,DBAASPR_4142,Not available,"m2386",DSIRDVSPTFNKIRRWFDGLFK,22,Q035J6##K0MXK3,Not available,"Lactobacillus casei; Lactobacillus paracasei",Native peptide,"Not available","H184B5F5/M10: ~20% Cell death=40 µg/ml; CHO-K1: ~35% Cell death=40 µg/ml","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep02326,Not available,DCTPep02326.cif,ACP##Tumor active peptide##Induce apoptosis,Not available,Linear,"Not available","Free",Free,None,L,2698.08,2696.42,9.98,ACEHMQY,DFR,C124H189N35O33,2,3,5,5,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.038","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",101.64,66.36,-0.686,"25557887++Antimicrobial peptide m2163 or m2386 identified from Lactobacillus casei ATCC 334 can trigger apoptosis in the human colorectal cancer cell line SW480++10.1007/s13277-014-3018-2++2015",Not available,Not available,"Not available",Not available,positive
DCTPep02329,Not available,Not available,DBAASPR_4194,Not available,"Jindongenin-1a",DSMGAVKLAKLLIDKMKCEVTKAC,24,G3ETQ2##G3F826,Not available,"Amolops jingdongensis",Native peptide,"Human erythrocytes: 50% Hemolysis=150 µM; Rabbit erythrocytes: 50% Hemolysis=150 µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep02329,Not available,DCTPep02329.cif,ACP##Tumor active peptide,Not available,Cyclic,"Cys18<--->Cys24","Free",Free,None,L,2596.22,2594.37,8.79,FHNPQRWY,K,C111H199N29O33S4,2,3,5,5,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.048, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",30.61,101.67,0.275,"21816202++Two novel families of antimicrobial peptides from skin secretions of the Chinese torrent frog, Amolops jingdongensis++10.1016/j.biochi.2011.07.021++2012",Not available,Not available,"Not available",Not available,positive
DCTPep06828,Not available,Not available,Not available,Not available,"SALF",ECKFTVKPYLKRFQVYYKGRMWCP,24,Not available,Not available,"Penaeus monodon",Synthetic peptide,"Not available","Not available","Not available",Not available,"SALF can induce apoptotic gene expressions, enhance antitumor activity of cisplatin in vitro, and inhibit tumor growth in nude mice.",Anticancer; Antimicrobial,Not available,Not available,Not available,Not available,ACP##Tumor active peptide##Membrane lysis##Induce apoptosis,Not available,Cyclic,"Cys2<--->Cys23","Acetylation",Amidation,None,L,3071.71,3069.55,9.70,ADHINS,K,C145H216N36O32S3,5,1,6,7,"Ext. coefficient    10095##Abs 0.1% (=1 g/l)   3.286, assuming all pairs of Cys residues form cystines##Ext. coefficient     9970##Abs 0.1% (=1 g/l)   3.246, assuming all Cys residues are reduced","1 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",36.94,40.42,-0.667,"20214941++Shrimp anti-lipopolysaccharide factor peptide enhances the antitumor activity of cisplatin in vitro and inhibits HeLa cells growth in nude mice++10.1016/j.peptides.2010.02.023++2010",Not available,Not available,"Not available",Not available,positive
DCTPep04855,Not available,Not available,Not available,Not available,"pTnI",EDMNQKLFDLRGKFKRPPLRRVRMSADAML,30,Not available,Not available,"Troponin I",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,3620.31,3617.92,10.88,CHITWY,R,C157H264N50O42S3,4,4,8,3,"Should not be visible by UV spectrophotometry.","1 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",71.64,68.33,-0.843,"21470139++Anti-angiogenic peptides for cancer therapeutics++10.2174/138920111796117300++2011",Not available,Not available,"Not available",Not available,positive
DCTPep03706,Not available,Not available,11541,Not available,"E10-Ctn[15-34]",EEEEEEEEEEKKRLKKIFKKPMVIGVTIPF,30,U5KJM4,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,3663.24,3660.93,4.83,ACDHNQSWY,E,C165H269N39O52S1,-3,10,7,2,"Should not be visible by UV spectrophotometry.","1 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",105.27,71.33,-1.133,"30042491++An acidic model pro-peptide affects the secondary structure, membrane interactions and antimicrobial activity of a crotalicidin fragment++Not available++2018",Not available,Not available,"Not available",Not available,positive
DCTPep04093,Not available,Not available,17031,Not available,"PN-CATH2",EGCNILCLLKRKVKAVKNVVKNVVKSVVG,29,Not available,Not available,"Animalia",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Free,None,L,3138.91,3136.87,10.05,DFHMPQTWY,V,C139H253N41O36S2,6,1,7,8,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.040, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",36.58,137.24,0.441,"33242568++Identification and characterization of novel bi-functional cathelicidins from the black-spotted frog (Pelophylax nigromaculata) with both anti-infective and antioxidant activities++Not available++2021",Not available,Not available,"Not available",Not available,positive
DCTPep01982,Not available,Not available,DBAASPS_14056,Not available,"E-I",EIIKKIIKKIIKKI,14,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 5% Hemolysis=300 µM; Human erythrocytes: 7% Hemolysis=500 µM","Human chondrocytes-articular cells Hca: 23% Killing=40 µM","Not available",Not available,"Not available",Anticancer,Not available,DCTPep01982,Not available,DCTPep01982.cif,ACP##Tumor active peptide##Membrane-targeted,Not available,Linear,"Not available","Free",Amidation,None,L,1708.29,1707.21,10.30,ACDFGHLMNPQRSTVWY,I,C83H158N20O17,5,1,6,0,"Should not be visible by UV spectrophotometry.","1 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-13.34,195.00,0.329,"27644109++Surface Physical Activity and Hydrophobicity of Designed Helical Peptide Amphiphiles Control Their Bioactivity and Cell Selectivity++10.1021/acsami.6b08297++2016",Not available,Not available,"Not available",Not available,positive
DCTPep02620,Not available,Not available,DBAASPN_5449,Not available,"Gageostatin A",ELLVDLL,7,Not available,139585758,"Bacillus subtilis",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide##Lipopeptides,Not available,Linear,"Not available","3-β-hydroxy-11-methyltridecanoic",Free,None,L,813.99,813.48,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Not Applicable","Not Applicable",Not Applicable,Not Applicable,Not Applicable,"24492520++Gageostatins A-C, antimicrobial linear lipopeptides from a marine Bacillus subtilis++10.3390/md12020871++2014",Not available,Not available,"Not available",Not available,positive
DCTPep02621,Not available,Not available,DBAASPN_5450,Not available,"Gageostatin B",ELLVDLL,7,Not available,139587549,"Bacillus subtilis",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide##Lipopeptides,Not available,Linear,"Not available","3-β-hydroxy-9,11-dimethyltridecanoic acids",Free,None,L,813.99,813.48,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Not Applicable","Not Applicable",Not Applicable,Not Applicable,Not Applicable,"24492520++Gageostatins A-C, antimicrobial linear lipopeptides from a marine Bacillus subtilis++10.3390/md12020871++2014",Not available,Not available,"Not available",Not available,positive
DCTPep02622,Not available,Not available,DBAASPN_5451,Not available,"Gageostatin C",ELLVDLL,7,Not available,139583883,"Bacillus subtilis",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide##Lipopeptides,Not available,Linear,"Not available","(E)-7,9-dimethylundec-2-enoic acid",Free,None,L,813.99,813.48,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Not Applicable","Not Applicable",Not Applicable,Not Applicable,Not Applicable,"24492520++Gageostatins A-C, antimicrobial linear lipopeptides from a marine Bacillus subtilis++10.3390/md12020871++2014",Not available,Not available,"Not available",Not available,positive
DCTPep00499,Not available,Not available,Not available,Not available,"mt_T18S/L22 W/P27A",ESFSDWWKLLAE,12,Not available,Not available,"MDM2",Synthetic peptide,"Not available","Not available","MDM2",Not available,"target the p53–MDM4 interaction",Anticancer,Not available,Not available,Not available,Not available,ACP##Tumor active peptide##Cancer targeted peptides,Not available,Linear,"Not available","Free",Free,None,L,1510.67,1509.71,4.14,CGHIMNPQRTVY,ELSW,C72H99N15O21,-2,3,1,2,"Ext. coefficient    11000##Abs 0.1% (=1 g/l)   7.282","1 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",18.14,73.33,-0.467,"24830845++Design of p53-derived peptides with cytotoxicity on breast cancer++10.1007/s00726-014-1750-y++2014 ",Not available,Not available,"Not available",Not available,positive
DCTPep00500,Not available,Not available,Not available,Not available,"mt_S20A/L22 W/P27A",ETFADWWKLLAE,12,Not available,Not available,"MDM2",Synthetic peptide,"Not available","Not available","MDM2",Not available,"target the p53–MDM5 interaction",Anticancer,Not available,Not available,Not available,Not available,ACP##Tumor active peptide##Cancer targeted peptides,Not available,Linear,"Not available","Free",Free,None,L,1508.69,1507.73,4.14,CGHIMNPQRSVY,AELW,C73H101N15O20,-2,3,1,1,"Ext. coefficient    11000##Abs 0.1% (=1 g/l)   7.291","1 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",5.3,81.67,-0.242,"24830845++Design of p53-derived peptides with cytotoxicity on breast cancer++10.1007/s00726-014-1750-y++2014 ",Not available,Not available,"Not available",Not available,positive
DCTPep00501,Not available,Not available,Not available,Not available,"mt_L22 W/P27A",ETFSDWWKLLAE,12,Not available,Not available,"MDM2",Synthetic peptide,"Not available","Not available","MDM2",Not available,"target the p53–MDM2 interaction",Anticancer,Not available,Not available,Not available,Not available,ACP##Tumor active peptide##Cancer targeted peptides,Not available,Linear,"Not available","Free",Free,None,L,1524.69,1523.73,4.14,CGHIMNPQRVY,ELW,C73H101N15O21,-2,3,1,2,"Ext. coefficient    11000##Abs 0.1% (=1 g/l)   7.215","1 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",12.38,73.33,-0.458,"24830845++Design of p53-derived peptides with cytotoxicity on breast cancer++10.1007/s00726-014-1750-y++2014 ",Not available,Not available,"Not available",Not available,positive
DCTPep00132,Not available,Not available,Not available,Not available,"hP7",ETWRTEAPSATGQASSLLGGRLLGQ,25,P39060,Not available,"Human endostatin peptides",Native peptide,"Not available","Not available","α5β1 integrin, metalloproteinases",Not available,"Inhibition of endothelial cell proliferation, migration, and tube formation",Anticancer; Antiangiogenesis,Not available,DCTPep00132,Not available,DCTPep00132.cif,Cancer targeted peptides,Not available,Linear,"Not available","Free",Free,None,L,2586.84,2585.32,6.24,CDFHIKMNVY,GL,C110H180N34O38,0,2,2,10,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.126","1 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",35.94,74.40,-0.440,"15867360++A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity++10.1158/0008-5472.CAN-04-1833++2005",Not available,Not available,"Not available",Not available,positive
DCTPep00049,Not available,Not available,Not available,Not available,"FIV-NCSU1 HR2 T1972 (734-768)",EWYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQ,35,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: Not active up to 1025 µg/ml","Not available","Not available",Not available,"Not available",Anticancer; Antiviral,Not available,DCTPep00049,Not available,DCTPep00049.cif,Membrane-targeted,Not available,Linear,"Not available","Acetylation",Amidation,None,L,4299.82,4297.15,4.94,ACHPRS,Q,C191H297N51O60S1,-1,5,4,8,"Ext. coefficient     8480##Abs 0.1% (=1 g/l)   1.972","1 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",56.34,75.14,-1.203,"12186891++C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread++10.1128/jvi.76.18.9079-9086.2002++2002",Not available,Not available,"Not available",Not available,positive
DCTPep01598,Not available,Not available,Not available,Not available,"FLAK50 Z9",FAFAKIIAKIAKKII,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01598,Not available,DCTPep01598.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1675.18,1674.1,10.48,CDEGHLMNPQRSTVWY,I,C84H143N19O16,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.65,156.67,1.313,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01599,Not available,Not available,Not available,Not available,"FLAK50 Z7",FAFGKGIGKIGKKGL,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01599,Not available,DCTPep01599.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1520.88,1519.92,10.48,CDEHMNPQRSTVWY,G,C73H121N19O16,4,0,4,5,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-30.29,84.67,0.173,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01600,Not available,Not available,Not available,Not available,"FLAK50 Z2",FAFGKGIGKVGKKLL,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01600,Not available,DCTPep01600.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1562.96,1561.97,10.48,CDEHMNPQRSTWY,GK,C76H127N19O16,4,0,4,4,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-35.95,104.00,0.433,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep00100,Not available,Not available,Not available,Not available,"PTP2",FAGLAANFLPTIICKISYKC,20,Not available,Not available,"Synthetic",Synthetic peptide,"Human RBCs: less than 6% hemolysis at 100 μg/ml","HEK293: IC50>100 µg/ml","Not available",Not available,"Not available",Anticancer; Antimicrobial,Not available,DCTPep00100,Not available,DCTPep00100.cif,Induce apoptosis,Not available,Cyclic,"Cys14<--->Cys20","Free",Amidation,None,L,2173.66,2172.15,8.86,DEHMQRVW,AI,C102H161N23O25S2,2,0,2,7,"Ext. coefficient     1615##Abs 0.1% (=1 g/l)   0.743, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.685, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",7.37,112.50,1.050,"14499271++In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines++10.1016/s0196-9781(03)00194-3++2003",Not available,Not available,"Not available",Not available,positive
DCTPep01601,Not available,Not available,Not available,Not available,"FLAK50 Z3",FAKAIAKIAFGKGIGKVGKKLL,22,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01601,Not available,DCTPep01601.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2258.87,2257.44,10.70,CDEHMNPQRSTWY,K,C109H188N28O23,6,0,6,4,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-25.19,120.00,0.595,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01602,Not available,Not available,Not available,Not available,"FLAK50B",FAKALAKLAKKLL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01602,Not available,DCTPep01602.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1414.84,1413.94,10.48,CDEGHIMNPQRSTVWY,AKL,C69H123N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,150.77,0.738,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01603,Not available,Not available,Not available,Not available,"FLAK 17 C",FAKALKALLKALKAL,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01603,Not available,DCTPep01603.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1599.08,1598.06,10.48,CDEGHIMNPQRSTVWY,AL,C78H139N19O16,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.65,163.33,1.013,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01604,Not available,Not available,Not available,Not available,"FLAK50 Q1",FAKFLAKFLKKAL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01604,Not available,DCTPep01604.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1524.96,1523.96,10.48,CDEGHIMNPQRSTVWY,K,C78H125N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",2.7,113.08,0.738,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01605,Not available,Not available,Not available,Not available,"FLAK50 Z6",FAKGVGKVGKKAL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01605,Not available,DCTPep01605.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1302.63,1301.82,10.48,CDEHIMNPQRSTWY,K,C61H107N17O14,4,0,4,3,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-29.95,90.00,0.138,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01606,Not available,Not available,Not available,Not available,"FLAK50 Z8",FAKIIAKIAKIAKKIL,16,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01606,Not available,DCTPep01606.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1769.33,1768.21,10.60,CDEGHMNPQRSTVWY,IK,C87H157N21O17,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",0.19,171.25,1.050,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01608,Not available,Not available,Not available,Not available,"FLAK77",FAKKALKALKKL,12,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1358.78,1357.92,10.60,CDEGHIMNPQRSTVWY,K,C66H119N17O13,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.06,122.50,0.008,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01609,Not available,Not available,Not available,Not available,"D2A21",FAKKFAKKFKKFAKKFAKFAFAF,23,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01609,Not available,DCTPep01609.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2775.47,2773.64,10.90,CDEGHILMNPQRSTVWY,K,C144H212N32O24,9,0,9,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",3.03,26.09,-0.083,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01611,Not available,Not available,Not available,Not available,"FLAK 72",FAKKLAKKAKLAKKL,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01611,Not available,DCTPep01611.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1686.2,1685.14,10.78,CDEGHIMNPQRSTVWY,K,C81H148N22O16,7,0,7,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.65,104.67,-0.393,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01612,Not available,Not available,Not available,Not available,"FLAK 58",FAKKLAKKLAKAAL,14,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01612,Not available,DCTPep01612.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1500.93,1499.99,10.60,CDEGHIMNPQRSTVWY,AK,C72H129N19O15,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-2.84,119.29,0.264,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01614,Not available,Not available,Not available,Not available,"FLAK57",FAKKLAKKLAKLAL,14,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01614,Not available,DCTPep01614.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1543.02,1542.04,10.60,CDEGHIMNPQRSTVWY,K,C75H135N19O15,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-8.91,140.00,0.407,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01615,Not available,Not available,Not available,Not available,"FLAK 56",FAKKLAKKLAKLL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01615,Not available,DCTPep01615.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1471.94,1471,10.60,CDEGHIMNPQRSTVWY,K,C72H130N18O14,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,143.08,0.300,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01617,Not available,Not available,Not available,Not available,"SHIVA 10 PEPTIDE 71 + KWKL",FAKKLAKKLKKLAKKLAKKWKL,22,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01617,Not available,DCTPep01617.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2611.43,2609.77,11.00,CDEGHIMNPQRSTVY,K,C128H228N34O23,11,0,11,0,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.106","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-13.61,106.82,-0.673,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01618,Not available,Not available,Not available,Not available,"SHIVA DERIV P69 + KWKL",FAKKLAKKLKKLAKKLAKKWKL,22,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01618,Not available,DCTPep01618.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2611.43,2609.77,11.00,CDEGHIMNPQRSTVY,K,C128H228N34O23,11,0,11,0,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.106","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-13.61,106.82,-0.673,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01619,Not available,Not available,Not available,Not available,"Anubis-2",FAKKLAKKLKKLAKKLAKLAKKL,23,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01619,Not available,DCTPep01619.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2609.46,2607.81,11.00,CDEGHIMNPQRSTVWY,K,C126H234N34O24,11,0,11,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-16.27,123.48,-0.361,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01620,Not available,Not available,Not available,Not available,"SHIVA 10 AC",FAKKLAKKLKKLAKKLAKLALAL,23,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01620,Not available,DCTPep01620.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2537.35,2535.74,10.90,CDEGHIMNPQRSTVWY,K,C123H226N32O24,9,0,9,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.58,144.78,0.222,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01621,Not available,Not available,Not available,Not available,"Shiva-11",FAKKLAKKLKKLAKKLAKLALALKALALKAL,31,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01621,Not available,DCTPep01621.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,3346.41,3344.3,11.00,CDEGHIMNPQRSTVWY,K,C162H298N42O32,11,0,11,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.23,154.84,0.455,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01622,Not available,Not available,Not available,Not available,"SHIVA 11[(1-16)ME(2-9]-COOH",FAKKLAKKLKKLAKKLIGAVLKV,23,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01622,Not available,DCTPep01622.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2537.35,2535.74,10.90,CDEHMNPQRSTWY,K,C123H226N32O24,9,0,9,1,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-19.97,144.35,0.278,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01623,Not available,Not available,Not available,Not available,"FLAK 06R-AM",FAKKLAKKLKKLAKLALAK,19,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01623,Not available,DCTPep01623.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2111.78,2110.44,10.85,CDEGHIMNPQRSTVWY,K,C102H187N27O20,8,0,8,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.87,128.95,-0.021,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01624,Not available,Not available,Not available,Not available,"FLAK06 AM",FAKKLAKKLKKLAKLALAL,19,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01624,Not available,DCTPep01624.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2096.76,2095.43,10.78,CDEGHIMNPQRSTVWY,K,C102H186N26O20,7,0,7,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.87,149.47,0.384,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01625,Not available,Not available,Not available,Not available,"FLAK06 R-AC",FAKKLAKKLKKLAKLALAL,19,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01625,Not available,DCTPep01625.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2096.76,2095.43,10.78,CDEGHIMNPQRSTVWY,K,C102H186N26O20,7,0,7,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.87,149.47,0.384,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01627,Not available,Not available,Not available,Not available,"FLAK44 AM",FAKKLAKLAKKALAL,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01627,Not available,DCTPep01627.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1614.09,1613.08,10.60,CDEGHIMNPQRSTVWY,AK,C78H140N20O16,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-1.99,137.33,0.500,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01629,Not available,Not available,Not available,Not available,"FLAK26-D2",FAKKLAKLAKKLAKAL,16,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01629,Not available,DCTPep01629.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1742.27,1741.17,10.70,CDEGHIMNPQRSTVWY,K,C84H152N22O17,6,0,6,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-6.54,128.75,0.225,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01633,Not available,Not available,Not available,Not available,"FLAK 25 AM",FAKKLAKLAKKLAKLALAL,19,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01633,Not available,DCTPep01633.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2039.67,2038.38,10.70,CDEGHIMNPQRSTVWY,AKL,C99H179N25O20,6,0,6,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-8.4,154.74,0.684,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01634,Not available,Not available,Not available,Not available,"FLAK43 AM",FAKKLAKLAKKLLAL,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01634,Not available,DCTPep01634.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1656.17,1655.12,10.60,CDEGHIMNPQRSTVWY,KL,C81H146N20O16,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.65,156.67,0.633,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01635,Not available,Not available,Not available,Not available,"FLAK51",FAKKLAKLALKLAKL,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01635,Not available,DCTPep01635.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1656.17,1655.12,10.60,CDEGHIMNPQRSTVWY,KL,C81H146N20O16,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-18.97,156.67,0.633,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01636,Not available,Not available,Not available,Not available,"FLAK 75",FAKKLKKLAKKL,12,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1415.87,1414.98,10.70,CDEGHIMNPQRSTVWY,K,C69H126N18O13,6,0,6,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-19.13,114.17,-0.467,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01637,Not available,Not available,Not available,Not available,"FLAK71",FAKKLKKLAKLAKKL,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01637,Not available,DCTPep01637.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1728.28,1727.19,10.78,CDEGHIMNPQRSTVWY,K,C84H154N22O16,7,0,7,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-18.97,124.00,-0.260,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01638,Not available,Not available,Not available,Not available,"FLAG26-D3",FAKKLLAKALKL,12,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1343.76,1342.91,10.48,CDEGHIMNPQRSTVWY,KL,C66H118N16O13,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.06,155.00,0.650,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01640,Not available,Not available,Not available,Not available,"FLAK91B",FAKLAKKALAKLL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01640,Not available,DCTPep01640.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1414.84,1413.94,10.48,CDEGHIMNPQRSTVWY,AKL,C69H123N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,150.77,0.738,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01643,Not available,Not available,Not available,Not available,"FLAK50 Q5",FAKLFAKAFKKAL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01643,Not available,DCTPep01643.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1482.88,1481.91,10.48,CDEGHIMNPQRSTVWY,AK,C75H119N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-8.86,90.77,0.585,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01644,Not available,Not available,Not available,Not available,"FLAK50 Q9",FAKLFAKLAKKFAL,14,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01644,Not available,DCTPep01644.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1596.03,1595,10.48,CDEGHIMNPQRSTVWY,AK,C81H130N18O15,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-2.84,112.14,0.814,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01645,Not available,Not available,Not available,Not available,"FLAK50 Q4",FAKLLAKAFKKAL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01645,Not available,DCTPep01645.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1448.86,1447.93,10.48,CDEGHIMNPQRSTVWY,AK,C72H121N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-8.86,120.77,0.662,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01647,Not available,Not available,Not available,Not available,"FLAK50 Q7",FAKLLAKALKKFAL,14,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01647,Not available,DCTPep01647.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1562.02,1561.01,10.48,CDEGHIMNPQRSTVWY,AKL,C78H132N18O15,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-2.84,140.00,0.886,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01648,Not available,Not available,Not available,Not available,"FLAK50 Q6",FAKLLAKALKKFL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01648,Not available,DCTPep01648.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1490.94,1489.97,10.48,CDEGHIMNPQRSTVWY,KL,C75H127N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,143.08,0.815,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01650,Not available,Not available,Not available,Not available,"FLAK50D",FAKLLAKALKKLL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01650,Not available,DCTPep01650.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1456.92,1455.99,10.48,CDEGHIMNPQRSTVWY,L,C72H129N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,173.08,0.892,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01651,Not available,Not available,Not available,Not available,"FLAK 50N",FAKLLAKALKLKL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01651,Not available,DCTPep01651.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1456.92,1455.99,10.48,CDEGHIMNPQRSTVWY,L,C72H129N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-23.42,173.08,0.892,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01652,Not available,Not available,Not available,Not available,"FLAK50 Q3",FAKLLAKFLKKAL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01652,Not available,DCTPep01652.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1490.94,1489.97,10.48,CDEGHIMNPQRSTVWY,KL,C75H127N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,143.08,0.815,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01653,Not available,Not available,Not available,Not available,"FLAK80",FAKLLAKKLL,10,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1144.51,1143.77,10.30,CDEGHIMNPQRSTVWY,L,C57H101N13O11,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.98,176.00,0.990,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01655,Not available,Not available,Not available,Not available,"FLAK50K",FAKLLAKLAKAKA,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01655,Not available,DCTPep01655.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1372.76,1371.9,10.48,CDEGHIMNPQRSTVWY,A,C66H117N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,128.46,0.585,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01656,Not available,Not available,Not available,Not available,"FLAK50L",FAKLLAKLAKAKG,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01656,Not available,DCTPep01656.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1358.73,1357.88,10.48,CDEHIMNPQRSTVWY,AK,C65H115N17O14,4,0,4,1,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,120.77,0.415,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01657,Not available,Not available,Not available,Not available,"FLAK 50H",FAKLLAKLAKAKL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01657,Not available,DCTPep01657.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1414.84,1413.94,10.48,CDEGHIMNPQRSTVWY,AKL,C69H123N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,150.77,0.738,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01659,Not available,Not available,Not available,Not available,"FLAK50J",FAKLLAKLAKKAA,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01659,Not available,DCTPep01659.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1372.76,1371.9,10.48,CDEGHIMNPQRSTVWY,A,C66H117N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,128.46,0.585,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01660,Not available,Not available,Not available,Not available,"FLAK50C",FAKLLAKLAKKAL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01660,Not available,DCTPep01660.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1414.84,1413.94,10.48,CDEGHIMNPQRSTVWY,AKL,C69H123N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,150.77,0.738,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01661,Not available,Not available,Not available,Not available,"FLAK50 T4",FAKLLAKLAKKEL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01661,Not available,DCTPep01661.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1472.88,1471.95,10.00,CDGHIMNPQRSTVWY,KL,C71H125N17O16,3,1,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,143.08,0.331,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01662,Not available,Not available,Not available,Not available,"FLAK50 Q8",FAKLLAKLAKKFAL,14,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01662,Not available,DCTPep01662.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1562.02,1561.01,10.48,CDEGHIMNPQRSTVWY,AKL,C78H132N18O15,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-2.84,140.00,0.886,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01663,Not available,Not available,Not available,Not available,"FLAK50T7",FAKLLAKLAKKGL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01663,Not available,DCTPep01663.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1400.81,1399.93,10.48,CDEHIMNPQRSTVWY,KL,C68H121N17O14,4,0,4,1,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,143.08,0.569,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01664,Not available,Not available,Not available,Not available,"FLAK50 T3",FAKLLAKLAKKIL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01664,Not available,DCTPep01664.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1456.92,1455.99,10.48,CDEGHMNPQRSTVWY,KL,C72H129N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",4.45,173.08,0.946,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01666,Not available,Not available,Not available,Not available,"FLAK50",FAKLLAKLAKKLL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01666,Not available,DCTPep01666.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1456.92,1455.99,10.48,CDEGHIMNPQRSTVWY,L,C72H129N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,173.08,0.892,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01667,Not available,Not available,Not available,Not available,"FLAK50 T5",FAKLLAKLAKKSL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01667,Not available,DCTPep01667.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1430.84,1429.94,10.48,CDEGHIMNPQRTVWY,KL,C69H123N17O15,4,0,4,1,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,143.08,0.538,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01668,Not available,Not available,Not available,Not available,"FLAK50 T2",FAKLLAKLAKKVL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01668,Not available,DCTPep01668.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1442.89,1441.97,10.48,CDEGHIMNPQRSTWY,KL,C71H127N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,165.38,0.923,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01669,Not available,Not available,Not available,Not available,"FLAK 50G",FAKLLAKLAKLKL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01669,Not available,DCTPep01669.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1456.92,1455.99,10.48,CDEGHIMNPQRSTVWY,L,C72H129N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-23.42,173.08,0.892,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01670,Not available,Not available,Not available,Not available,"FLAK50I",FAKLLALALKLKL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01670,Not available,DCTPep01670.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1441.91,1440.98,10.30,CDEGHIMNPQRSTVWY,L,C72H128N16O14,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-23.42,203.08,1.485,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01671,Not available,Not available,Not available,Not available,"FLAK50 Q2",FAKLLFKALKKAL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01671,Not available,DCTPep01671.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1490.94,1489.97,10.48,CDEGHIMNPQRSTVWY,KL,C75H127N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-15.39,143.08,0.815,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01672,Not available,Not available,Not available,Not available,"FLAK 50E",FAKLLKLAAKKLL,13,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01672,Not available,DCTPep01672.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1456.92,1455.99,10.48,CDEGHIMNPQRSTVWY,L,C72H129N17O14,4,0,4,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-16.89,173.08,0.892,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01673,Not available,Not available,Not available,Not available,"FLAK50 Z4",FAKLWAKLAFGKGIGKVGKKLL,22,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01673,Not available,DCTPep01673.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2374,2372.48,10.70,CDEHMNPQRSTY,K,C117H193N29O23,6,0,6,4,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.317","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-25.11,115.45,0.409,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01674,Not available,Not available,Not available,Not available,"FLAK50 Z5",FAKLWAKLAKKL,12,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1416.82,1415.9,10.48,CDEGHIMNPQRSTVY,K,C71H117N17O13,4,0,4,0,"Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.882","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-4.85,122.50,0.258,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01675,Not available,Not available,Not available,Not available,"FLAK-120B",FALA,4,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Not Applicable","Not Applicable",Not Applicable,Not Applicable,Not Applicable,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01676,Not available,Not available,Not available,Not available,"FLAK01 AM",FALAAKALKKLAKKLKKLAKKAL,23,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01676,Not available,DCTPep01676.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2495.27,2493.7,10.90,CDEGHIMNPQRSTVWY,K,C120H220N32O24,9,0,9,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-8.89,132.17,0.135,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01678,Not available,Not available,Not available,Not available,"FLAK62 AM",FALAKKALKKAKKAL,15,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01678,Not available,DCTPep01678.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1629.11,1628.09,10.70,CDEGHIMNPQRSTVWY,K,C78H141N21O16,6,0,6,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",3.67,111.33,-0.013,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01679,Not available,Not available,Not available,Not available,"FLAK05 AM",FALAKLAKKAKAKLKKALKAL,21,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01679,Not available,DCTPep01679.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2253.93,2252.52,10.85,CDEGHIMNPQRSTVWY,K,C108H197N29O22,8,0,8,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-6.65,126.19,0.152,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01680,Not available,Not available,Not available,Not available,"FLAK94",FALALKA,7,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,732.92,732.45,8.75,CDEGHIMNPQRSTVWY,A,C36H60N8O8,1,0,1,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.56,154.29,1.700,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01681,Not available,Not available,Not available,Not available,"FLAK-120C",FALALKAKKL,10,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1102.43,1101.73,10.30,CDEGHIMNPQRSTVWY,AKL,C54H95N13O11,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.98,147.00,0.790,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01682,Not available,Not available,Not available,Not available,"FLAK96F",FALALKALKK,10,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1102.43,1101.73,10.30,CDEGHIMNPQRSTVWY,AKL,C54H95N13O11,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.98,147.00,0.790,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01686,Not available,Not available,Not available,Not available,"Hecate Ac",FALALKALKKALKKLKKALKKAL,23,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01686,Not available,DCTPep01686.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2537.35,2535.74,10.90,CDEGHIMNPQRSTVWY,K,C123H226N32O24,9,0,9,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.58,144.78,0.222,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01687,Not available,Not available,Not available,Not available,"Hecate AM",FALALKALKKALKKLKKALKKAL,23,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01687,Not available,DCTPep01687.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2537.35,2535.74,10.90,CDEGHIMNPQRSTVWY,K,C123H226N32O24,9,0,9,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.58,144.78,0.222,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01689,Not available,Not available,Not available,Not available,"FLAK04 AM",FALALKALKKLAKKLKKLAKKAL,23,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01689,Not available,DCTPep01689.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2537.35,2535.74,10.90,CDEGHIMNPQRSTVWY,K,C123H226N32O24,9,0,9,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.58,144.78,0.222,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01690,Not available,Not available,Not available,Not available,"FLAK06 AC",FALALKALKKLKKALKKAL,19,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01690,Not available,DCTPep01690.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2096.76,2095.43,10.78,CDEGHIMNPQRSTVWY,K,C102H186N26O20,7,0,7,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.87,149.47,0.384,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01691,Not available,Not available,Not available,Not available,"FLAK06 AM",FALALKALKKLKKALKKAL,19,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01691,Not available,DCTPep01691.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2096.76,2095.43,10.78,CDEGHIMNPQRSTVWY,K,C102H186N26O20,7,0,7,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.87,149.47,0.384,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01692,Not available,Not available,Not available,Not available,"FLAK03 AM",FALALKALKKLLKKLKKLAKKAL,23,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01692,Not available,DCTPep01692.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2579.43,2577.79,10.90,CDEGHIMNPQRSTVWY,K,C126H232N32O24,9,0,9,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-16.27,157.39,0.309,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01693,Not available,Not available,Not available,Not available,"FLAK 17 AM",FALALKKALKALKKAL,16,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01693,Not available,DCTPep01693.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1727.25,1726.16,10.60,CDEGHIMNPQRSTVWY,AKL,C84H151N21O17,5,0,5,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-6.54,153.12,0.706,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01694,Not available,Not available,Not available,Not available,"FLAK96B",FALALKLAKKAL,12,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1286.67,1285.85,10.30,CDEGHIMNPQRSTVWY,AL,C63H111N15O13,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-4.98,163.33,1.125,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01695,Not available,Not available,Not available,Not available,"Flak 96J",FALALKLAKKL,11,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1215.59,1214.81,10.30,CDEGHIMNPQRSTVWY,L,C60H106N14O12,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-14.06,169.09,1.064,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01012,Not available,Not available,16101,Not available,"Brevinin-1Ha",FALGAVTCLIRTKCKVLPKLF,21,Not available,Not available,"skin secretion of Amolops hainanensis ",Native peptide,"Not available","Horse blood cells: only over 20% at a concentration of 128 µM","Not available",Not available,"Not available",Anticancer; Antitumor; Antimicrobial,Not available,DCTPep01012,Not available,DCTPep01012.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2321.95,2320.35,9.85,DEHMNQSWY,L,C109H185N27O24S2,4,0,4,5,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.054, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",11.7,130.00,1.081,"32812694++Characterisation of a novel peptide, Brevinin-1H, from the skin secretion of Amolops hainanensis and rational design of several analogues++10.1111/cbdd.13779++2021",Not available,Not available,"Not available",Not available,positive
DCTPep01011,Not available,Not available,Not available,Not available,"Brevinin-1H",FALGAVTKVLPKLFCLITRKC,21,Not available,Not available,"skin secretion of Amolops hainanensis ",Native peptide,"Not available","Horse blood cells: HC50=53.12 µM","Not available",Not available,"Not available",Anticancer; Antitumor; Antimicrobial,Not available,DCTPep01011,Not available,DCTPep01011.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2321.95,2320.35,9.85,DEHMNQSWY,L,C109H185N27O24S2,4,0,4,5,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.054, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",11.7,130.00,1.081,"32812694++Characterisation of a novel peptide, Brevinin-1H, from the skin secretion of Amolops hainanensis and rational design of several analogues++10.1111/cbdd.13779++2021",Not available,Not available,"Not available",Not available,positive
DCTPep01013,Not available,Not available,Not available,Not available,"Brevinin-1HY",FALGAVTKVLYKLFCLITRKC,21,Not available,Not available,"skin secretion of Amolops hainanensis ",Native peptide,"Not available","Horse blood cells: The haemolysis at the MIC of Brevinin-1HY (28.48%) was more than threefold at the MIC for the parent peptide","Not available",Not available,"Not available",Anticancer; Antitumor; Antimicrobial,Not available,DCTPep01013,Not available,DCTPep01013.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2388.01,2386.36,9.70,DEHMNPQSW,L,C113H187N27O25S2,4,0,4,6,"Ext. coefficient     1615##Abs 0.1% (=1 g/l)   0.676, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.624, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",2.52,130.00,1.095,"32812694++Characterisation of a novel peptide, Brevinin-1H, from the skin secretion of Amolops hainanensis and rational design of several analogues++10.1111/cbdd.13779++2021",Not available,Not available,"Not available",Not available,positive
DCTPep01699,Not available,Not available,Not available,Not available,"FLAK95",FALKALKKLKKALKKAL,17,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01699,Not available,DCTPep01699.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1912.52,1911.31,10.78,CDEGHIMNPQRSTVWY,K,C93H170N24O18,7,0,7,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-15.56,138.24,0.100,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep01701,Not available,Not available,Not available,Not available,"Flak 96I",FALLKALLKKAL,12,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,Not available,Not available,Not available,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,1328.75,1327.9,10.30,CDEGHIMNPQRSTVWY,L,C66H117N15O13,3,0,3,0,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-4.98,187.50,1.292,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep00671,Not available,Not available,Not available,Not available,"Temporin-1Sa [L2,9A;V6A]",FASGIAGMAGKLF,13,Not available,Not available,"Synthetic",Synthetic peptide,"Rat erythrocytes: 50% Hemolysis>200µM; Human erythrocytes: 50% Hemolysis	>100µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep00671,Not available,DCTPep00671.cif,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,1269.52,1268.66,8.75,CDEHNPQRTVWY,AG,C59H92N14O15S1,1,0,1,4,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-0.87,83.08,1.177,"28319176++Insight into the mechanism of action of temporin-SHa, a new broad-spectrum antiparasitic and antibacterial agent++10.1371/journal.pone.0174024++2017",Not available,Not available,"Not available",Not available,positive
DCTPep01703,Not available,Not available,Not available,Not available,"FAGVL",FAVGLRAIKRALKKLRRGVRKVAKDL,26,Not available,Not available,"FLAK peptides",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep01703,Not available,DCTPep01703.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2963.7,2961.9,12.19,CEHMNPQSTWY,KR,C134H244N46O29,9,1,10,2,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",39.41,123.85,-0.154,"Not available++Not available++Not available++Not available",US2005/0209157A1,Short bioactive peptides and methods for their use,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",Not available,positive
DCTPep04862,Not available,Not available,Not available,Not available,"Pentastatin-2",FCNINNVCNFASRNDYSYW,19,Not available,Not available,"Homo sapiens (α5 CIV)",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Not available,"Not available","Free",Free,None,L,2330.53,2328.97,5.82,EGHKLMPQT,N,C103H140N28O31S2,0,1,1,11,"Ext. coefficient     8605##Abs 0.1% (=1 g/l)   3.692, assuming all pairs of Cys residues form cystines##Ext. coefficient     8480##Abs 0.1% (=1 g/l)   3.639, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",35.86,41.05,-0.500,"18780781++A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells++10.1073/pnas.0803241105++2008",Not available,Not available,"Not available",Not available,positive
DCTPep04760,DRAMP01616,Not available,Not available,Not available,"Aurein-3.1.2",FDIVKKIAGHIAGSI,15,P69021,Not available,"Litoria aurea",Native peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,1568.88,1567.91,8.60,CELMNPQRTWY,I,C73H121N19O19,2,1,3,3,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",33.61,136.67,0.833,"10951191++The antibiotic and anticancer active aurein peptides from the Australian Bell Frogs Litoria aurea and Litoria raniformis the solution structure of aurein 1.2++10.1046/j.1432-1327.2000.01536.x++2000",Not available,Not available,"Not available",Not available,positive
DCTPep00491,Not available,Not available,Not available,Not available,"Trichoplaxin",FFGRLKSVWSAVKHGWKAAKSR,22,Not available,Not available,"Trichoplax adhaerens",Native peptide,"Rat erythrocytes:20% Hemolysis=800µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep00491,Not available,DCTPep00491.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2547.01,2545.42,12.03,CDEIMNPQTY,K,C120H184N36O26,7,0,7,5,"Ext. coefficient    11000##Abs 0.1% (=1 g/l)   4.319","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",14.03,57.73,-0.436,"24530880++Trichoplaxin - a new membrane-active antimicrobial peptide from placozoan Cdna++10.1016/j.bbamem.2014.02.003++2014",Not available,Not available,"Not available",Not available,positive
DCTPep02083,Not available,Not available,DBAASPR_2370,Not available,"Piscidin 1",FFHHIFRGIVHVGKTIHRLVTG,22,Q8UUG0,Not available,"Morone saxatilis (Striped bass) (Perca saxatilis)",Native peptide,"Human erythrocytes: 50% Hemolysis=3.12 µg/ml; 100% Hemolysis=25 µg/ml","HEK293: LC90=50 µg/ml (>90% cells killed)","Not available",Not available,"Not available",Anticancer; Antimicrobial; Antifungal; Antiviral; Anti-Inflammatory,Not available,DCTPep02083,2MCU ,DCTPep02083.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2572.06,2570.45,12.01,ACDEMNPQSWY,H,C122H187N37O25,7,0,7,5,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",8.11,110.45,0.455,"34135370++Copper-binding anticancer peptides from the piscidin family: an expanded mechanism that encompasses physical and chemical bilayer disruption++10.1038/s41598-021-91670-w++2021##31354312++Substitution of lysine for isoleucine at the center of the nonpolar face of the antimicrobial peptide, piscidin-1, leads to an increase in the rapidity of bactericidal activity and a reduction in toxicity++10.2147/IDR.S195872++2019",Not available,Not available,"Not available",Not available,positive
DCTPep02084,Not available,Not available,Not available,Not available,"Piscidin 1 Cu2+",FFHHIFRGIVHVGKTIHRLVTG,22,Not available,Not available,"Morone saxatilis (Striped bass) (Perca saxatilis)",Native peptide,"Not available","Not available","Not available",Not available,"Metallating HDPs is an effective strategy to enhance their anticancer properties through the expansion of their mechanism of action, so that both physical and chemical damage of membranes is achieved.",Anticancer; Antimicrobial; Antifungal; Antiviral; Anti-Inflammatory,Not available,DCTPep02084,Not available,DCTPep02084.cif,ACP##Tumor active peptide,Not available,Linear,"Coordination bond: Phe1<---Cu2+--->Phe1 (Amine); Phe1<---Cu2+--->Phe2 (Amide); Phe1<---Cu2+--->His3 (Imidazole)","Free",Free,None,L,2572.06,2570.45,12.01,ACDEMNPQSWY,H,C122H187N37O25,7,0,7,5,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",8.11,110.45,0.455,"34135370++Copper-binding anticancer peptides from the piscidin family: an expanded mechanism that encompasses physical and chemical bilayer disruption++10.1038/s41598-021-91670-w++2021##31354312++Substitution of lysine for isoleucine at the center of the nonpolar face of the antimicrobial peptide, piscidin-1, leads to an increase in the rapidity of bactericidal activity and a reduction in toxicity++10.2147/IDR.S195872++2019",Not available,Not available,"Not available",Not available,positive
DCTPep03694,Not available,Not available,11271,Not available,"Stigmurin [S3,7K;G10K], StigA16",FFKLIPKLVKGLISAFK,17,Not available,Not available,"Synthetic",Synthetic peptide,"Not available","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial; Antiparasitic; Antifungal,Not available,Not available,Not available,Not available,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,1949.5,1948.23,10.48,CDEHMNQRTWY,K,C99H161N21O19,4,0,4,2,"Should not be visible by UV spectrophotometry.","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-26.64,137.65,0.965,"29670004++Analogs of the Scorpion Venom Peptide Stigmurin: Structural Assessment, Toxicity, and Increased Antimicrobial Activity++Not available++2018",Not available,Not available,"Not available",Not available,positive
DCTPep00662,Not available,Not available,Not available,Not available,"Brevinin1 HYba2",FFPGIIKVAGAILPTAICAITKRC,24,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 60% Hemolysis=50µM; 85% Hemolysis=100µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00662,Not available,DCTPep00662.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2504.13,2502.42,9.50,DEHMNQSWY,I,C117H195N29O27S2,3,0,3,6,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.050, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",33.09,126.25,1.275,"28072492++Identification and characterization of novel host defense peptides from the skin secretion of the fungoid frog, Hydrophylax bahuvistara (Anura: Ranidae)++10.1111/cbdd.12937++2018",Not available,Not available,"Not available",Not available,positive
DCTPep00663,Not available,Not available,Not available,Not available,"Brevinin1 HYba2 AMD",FFPGIIKVAGAILPTAICAITKRC,24,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 40% Hemolysis=50µM; 50% Hemolysis=100µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00663,Not available,DCTPep00663.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2504.13,2502.42,9.50,DEHMNQSWY,I,C117H195N29O27S2,3,0,3,6,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.050, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",33.09,126.25,1.275,"28072492++Identification and characterization of novel host defense peptides from the skin secretion of the fungoid frog, Hydrophylax bahuvistara (Anura: Ranidae)++10.1111/cbdd.12937++2018",Not available,Not available,"Not available",Not available,positive
DCTPep00664,Not available,Not available,Not available,Not available,"Brevinin1 HYba1",FFPGIIKVASAILPTAICAITKRC,24,Not available,Not available,"Hydrophylax bahuvistara",Native peptide,"Human erythrocytes:60% Hemolysis=50µM; 80% Hemolysis=100µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00664,Not available,DCTPep00664.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Free,None,L,2534.16,2532.43,9.50,DEHMNQWY,I,C118H197N29O28S2,3,0,3,6,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.049, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",36.63,126.25,1.258,"28072492++Identification and characterization of novel host defense peptides from the skin secretion of the fungoid frog, Hydrophylax bahuvistara (Anura: Ranidae)++10.1111/cbdd.12937++2018",Not available,Not available,"Not available",Not available,positive
DCTPep00665,Not available,Not available,Not available,Not available,"Brevinin1 HYba1 AMD",FFPGIIKVASAILPTAICAITKRC,24,Not available,Not available,"Hydrophylax bahuvistara",Native peptide,"Human erythrocytes:30% Hemolysis=50µM; 40% Hemolysis=100µM","Not available","Not available",Not available,"Not available",Anticancer; Antibacterial,Not available,DCTPep00665,Not available,DCTPep00665.cif,ACP##Tumor active peptide,Not available,Linear,"Not available","Free",Amidation,None,L,2534.16,2532.43,9.50,DEHMNQWY,I,C118H197N29O28S2,3,0,3,6,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.049, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",36.63,126.25,1.258,"28072492++Identification and characterization of novel host defense peptides from the skin secretion of the fungoid frog, Hydrophylax bahuvistara (Anura: Ranidae)++10.1111/cbdd.12937++2018",Not available,Not available,"Not available",Not available,positive
DCTPep00298,Not available,Not available,Not available,Not available,"NRC-09",FFRLLFHGVHHGGGYLNAA,19,Not available,Not available,"Synthetic",Synthetic peptide,"Human erythrocytes: 50% Hemolysis>256 µg/ml","Zebrafish embryos: No Killing","Not available",Not available,"Not available",Anticancer; Antibacterial; Antifungal,Not available,DCTPep00298,Not available,DCTPep00298.cif,Cancer therapy related peptides,Not available,Linear,"Not available","Free",Amidation,None,L,2113.41,2112.08,8.77,CDEIKMPQSTW,G,C101H141N29O22,4,0,4,6,"Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.705","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",7.08,87.37,0.374,"21729875++The zebrafish embryo as a tool for screening and characterizing pleurocidin host-defense peptides as anti-cancer agents++10.1242/dmm.007310++2011",Not available,Not available,"Not available",Not available,positive
